Skip to main content
Cell Proliferation logoLink to Cell Proliferation
. 2024 Jul 11;57(12):e13705. doi: 10.1111/cpr.13705

Memory inflation: Beyond the acute phase of viral infection

Yanfei Li 1, Jie Xiao 2, Chen Li 2,, Mu Yang 1,2,
PMCID: PMC11628752  PMID: 38992867

Abstract

Memory inflation is confirmed as the most commonly dysregulation of host immunity with antigen‐independent manner in mammals after viral infection. By generating large numbers of effector/memory and terminal differentiated effector memory CD8+ T cells with diminished naïve subsets, memory inflation is believed to play critical roles in connecting the viral infection and the onset of multiple diseases. Here, we reviewed the current understanding of memory inflated CD8+ T cells in their distinct phenotypic features that different from exhausted subsets; the intrinsic and extrinsic roles in regulating the formation of memory inflation; and the key proteins in maintaining the expansion and proliferation of inflationary populations. More importantly, based on the evidences from both clinic and animal models, we summarized the potential mechanisms of memory inflation to trigger autoimmune neuropathies, such as Guillain‐Barré syndrome and multiple sclerosis; the correlations of memory inflation between tumorigenesis and resistance of tumour immunotherapies; as well as the effects of memory inflation to facilitate vascular disease progression. To sum up, better understanding of memory inflation could provide us an opportunity to beyond the acute phase of viral infection, and shed a light on the long‐term influences of CD8+ T cell heterogeneity in dampen host immune homeostasis.


This review highlights the definition of virus‐induced CD8+ T cell memory inflation,as well as the impacts on multi‐diseases progression. By summarizing current understandings, an opportunity is provided for shedding a light on the long‐term influences of memory inflation in host‐immune homeostasis thus beyond the acute phase of infection.

graphic file with name CPR-57-e13705-g003.jpg

1. INTRODUCTION

The global outbreak of COVID‐19, caused by novel coronavirus, has affected people worldwide. 1 Other than a significant portion suffering from systemic inflammation and respiratory failure during the acute phase, epidemiological studies have proved that majority of patients only experienced mild symptoms or even showed asymptomatic throughout the infection. 2 , 3 However, in neglecting the severity of their symptoms at acute phase, the whole infected population were reported to obtain alternative host immune backgrounds after recovery, especially the dynamic changes of CD8+ T cell subsets, functions, and responsiveness. 4 Preciously studies have already documented that the most prominent characteristic of CD8+ T cells in post‐infection is the high turnover rate of memory phenotype without virus antigen participation. 5 , 6 , 7 Unfortunately, few evidences emerged to reveal the associations between this immune heterogeneity with any clinical manifestations, until immune abnormalities‐mediated diseases are rising in recovered patients of COVID‐19 infection, such as idiopathic interstitial pneumonia, autoimmune neuropathies and tumorigenesis. 8 Therefore, growing attentions are paid to the post‐infection induced dysregulation of CD8+ T cells, which might be one of the decisive triggers for such immunological disorders, and/or bring poor prognosis to patients. 9 , 10

Apart from COVID‐19, cytomegalovirus (CMV) infection is the most potent factor in mediating similar immunophenotypes of CD8+ T cells. Different from post‐infection of lymphocytic choriomeningitis virus (LCMV), which primarily leads to exhaustion phenotypes of CD8+ T cells for resisting viral colonization in somatic cells, CMV provokes CD8+ T cells after virus clearance due to immunological memory. 11 The expansion of CD8+ T cells by CMV is confirmed to produce large number of memory‐like T cells, including memory precursor (MP), effector/memory (E/M), as well as terminal differentiated effector memory (EMRA) subsets with antigen‐independent manner in both animal models and human population. 12 , 13 , 14 This exclusive phenotype known as “memory inflation,” is also commonly observed after vaccination, and described as a life‐long “population expansion” of CD8+ memory T cells in circulating system. 11 , 15 Notably, similar with COVID‐19 infection, recent reports revealed that excessive differentiation of memory‐inflated CD8+ T cells after CMV infection exhibits a close relationship with both autoimmunity and tumorigenesis. 16 , 17 , 18 , 19

The latest research studies have largely explored the mechanisms underlying memory‐ inflated CD8+ T cells, including their characteristics, key molecules involved in this unique phenotypic differentiation and expansion, as well as the alternative immune functions of inflationary CD8+ T cells. 20 , 21 , 22 , 23 Thus, to better understand the potential roles of memory inflation in mediating disease onset, progression, and side effects during treatment, we in‐depth review the current knowledge in the molecular features of memory‐inflated CD8+ T cells, along with the differentiation patterns. Additionally, the critical roles of CD8+ T cells with memory inflation phenotype in autoimmune diseases of nervous system, treatment resistance of cancer immunotherapies, and vascular disorders would be also addressed.

2. DEFINITION OF MEMORY INFLATION

2.1. Basic concept of memory inflation

The concept of memory inflation was firstly introduced according to the report of continuous accumulations of viral antigen specific CD8+ T cells in 2003. 24 By using murine CMV (MCMV), a C57BL/6‐based murine model was generated to investigate the significant accumulation of MCMV IE1 protein (pp89, also known as m123/phosphoprotein)‐specific CD8+ T cells. 25 After 1 year post‐infection, inflated populations could still be observed in both circulating system and multi‐organs. 25 This phenomenon, termed memory inflation, was hypothesized to begin shortly after primary infection and persist a long period without viral‐antigen participation. 24 Subsequent studies confirmed that CMV‐mediated cellular immunity in patients could initiate a similar memory inflation of CD8+ T cells, and further investigations also revealed a long‐term expansion of antigen‐specific CD8+ T cells in the context of vaccination. 25 , 26 Interestingly, other than CMV, similar inflationary CD8+ T cells could be also induced by viruses that do not establish latency, such as replication‐defective adenovirus, polyomavirus, and parvovirus. 27 , 28 However, CMV remains the most efficient trigger in bringing memory inflation of both human and rodent models. 28

The initial priming of CMV infection involves a hierarchical and redundant process, with the involvements of type I and II interferons (IFN‐α/β and IFNγ), natural killer (NK) cells from innate immune system, and CD4+ and CD8+ T cells that belong to adaptive immunity. 29 Upon viral infection, IFN‐α/β and IFNγ activated NK cells to provide early antiviral responses, followed by clonal expansion and differentiation of naïve (N) CD8+ T cells into effector (E) populations on basis of adaptive immune responses against viral infection. 30 Subsequently, CD8+ TE cells are responsible for controlling infection and reactivating to latent infection until eliminating the viral titers. 24 , 31 At the same time, a small amount of primed CD8+ T cells give rise to phenotypically diverse TMP subsets that are categorized by their homing property, cytokine polyfunctionality, and cytolytic capacity. 32 , 33 Due to continuous exposure to latently expressed antigens, expansion and asymmetric differentiation are initiated in those TMP cells that specifically recognized viral antigens. 21 As a result, high frequencies of memory‐like CD8+ T cells expanded and eventually stabilized with distinct profiles, such as CD8+ TE/M and TEMRA cells (Figure 1). 34 , 35 , 36 In this process, both percentile and absolute numbers of CD8+ TN cells were monitored to constantly decline. 13 , 37 Longitudinal study on CMV infection spanning 27 years also mentioned that CMV seropositive individuals have significantly higher numbers of CD8+ TE/M and TEMRA cells, whereas the percentile of CD8+ TN cells and T central memory (CM) populations remain decreasing. 38 In fact, compared to non‐inflated T cells, inflated T cells present at high frequencies in both blood and tissues, such as liver and lung. 39 And the average fraction of CMV‐specific cells within the general memory compartments may exceed 10% in inflated status. 40 Therefore, the immunological aspect of memory inflation could be generally defined as redundant CD8+ TE/M cells with diminished CD8+ TN cells in circulating system. 27 , 41 , 42 , 43

FIGURE 1.

FIGURE 1

The host's immune responses to CMV infection. Upon viral infection, IFN‐α/β and IFNγ activated NK cells to provide an early antiviral response, followed by clonal expansion and differentiation of CD8+ TN cells into TE. And then a small amount of primed CD8+ T cells give rise to phenotypically diverse CD8+ TMP cells, which expanded and eventually stabilized as CD8+ TE/M and TEMRA cells. NK, Natural Killer; TN, Naïve T cells; TE, Effector T cells; TMP, Memory precursor T cells; TE/M, Effector/Memory T cells; TEMRA, terminally differentiated effector memory T cells.

2.2. Phenotypic features of memory inflated CD8 + TE /M cells

Virus‐specific memory CD8+ T cells could be mainly categorized into three populations based on their phenotypic features and tissue distributions: TCM, TE/M, and TEMRA cells, whereas CD8+ TE/M cells are considered as the predominant population among them. 35 , 44 Accordingly, TCM cells possess homing property and primarily reside in secondary lymphoid organs, along with excellent sensitivity to the proliferative cytokines interleukin‐7 (IL‐7) and interleukin‐15 (IL‐15). 42 , 45 , 46 Besides, TE/M and TEMRA cells exhibit a terminally differentiated phenotype with cytolytic functions, are predominantly found in circulating system, but often patrolling at the site of peripheral organs with primary infection. 41 , 42 , 43 , 46 Actually, on account of the sophisticated trajectories among TCM, TE/M and TEMRA cells under certain conditions, various markers are currently used to distinguish TE/M cells from inflationary population. 26 In general, CD8+ T cells under memory inflation display a highly differentiated phenotype, which are characterized by reductions of homing markers (CD62L and CCR7). 43 As the sign of TCM cells, IL15Rβ (CD122) is also downregulated in CD8+ TE/M cells. 47 , 48 Meanwhile, T cell Ig and ITIM domain (TIGIT) expression is found to decrease in CD8+ TE/M cells for retaining the secretion of Grazyme B and perforin. 49 And low level of IL7Rα (CD127) expression in primed CD8+ T cells implies the transition of TMP to TE/M and TEMRA phenotypes. 50 On the other hand, significant elevating of CD25 and CD69 expressions were observed in CD8+ TE/M cells as well. 51 But consistently expression pattern of killer cell lectin‐like receptor G1 (KLRG1) exerts inhibitory effects on CD8+ TE/M cells for preventing excessive activation. 52 In murine models of memory inflation, stemness marker CD44 is detected to constitutively express from the generation of CD8+ TMP cells to CD8+ TE/M population formation. 53 Moreover, CMV‐specific CD8+ TE/M cells from patients own high expressions of CD45RO during primary infection, but sequentially enrich CD45RA upon the chronic phase. 54 According to the alternative immune functions of CD45 isoforms, co‐stimulatory signals were confirmed to be needed for the maintenance of CD8+ TE/M population, which bring the expressions of co‐receptors (CD27 and CD28). 55 , 56 Recent studies identified that asymmetric differentiation could cause certain amount of CD8+ TE/M cells express the replicative senescence markers, such as CD57 and CD85 to further shape the CD8+ TEMRA population. 57 , 58 Simultaneously, expanded CD8+ TE/M population was detected to possess high expression of CX3C‐chemokine receptor 1 (CX3CR1) that allows them to interact with endothelial cells and receive survival signals from antiapoptotic protein BCL‐XL. 11 Collectively, co‐expression of CD25, CD69, KLRG1, CD27, CD28 and CD45RO (CD44 for murine model) in combine with the reduction of TIGIT, CD127, CD122, CD62L, and CCR7 in CD8+ T cells is used as current strategy to categorize CD8+ TE/M cells, whereas expressions of CX3CR1, CD57 and CD85 are usually to further dissect the TEMRA cells from CD8+ TE/M subset, or distinguish CD8+ TE cells in recall responses that mediated by CD8+ TCM and TE/M cells (Table 1). 59

TABLE 1.

Characteristics of Virus‐specific CD8+ T cells.

Central memory Inflationary Exhausted
Homeostatic proliferation ++
Antigen dependence ++ ++
Cytokine polyfunctionality ++ + (low% IL‐2)
Homing markers
CD62L ++
CCR7 ++
CX3CR1 +/−
CD44 ++
Cytokine receptors
CD122 ++
CD127 ++ +/−
Natural killer receptors
KLRG1 ++
CD57 +/−
CD85 +/−
Co‐stimulatory receptors
CD28 +
CD27 ++
Inhibitory receptors
PD‐1/CTLA‐4/LAG3/TIM3/ etc. ++
Transcription factors
T‐BET + +/−
EOMES +/− +

Note: − absent or low, +/− intermediate, + high, ++ prominent.

Irrespective of their dynamic expressions of surface markers, CD8+ T cells initially express Granzyme B and perforin at acute phase of CMV infection, and then efficiently produce high levels of IFNγ and tumour necrosis factor (TNF) during the latent phase. 26 , 60 Accordingly, CD8+ TEMRA cells appear at the latent phase of infection have more robust ability to secret IFNγ and TNF. 61 Interestingly, except of the secondary responses, Granzyme B and perforin are almost completely absent at the latent phase. 26 In contrast, investigations from post‐infected patients indicated that circulating CD8+ TE/M cells emerge the ability to express Granzyme B and perforin, although the secreting levels vary depend on the heterogeneities of individuals. 62 , 63 Furthermore, TNF level of CD8+ TE/M cells is found to decrease in infected patients by comparing with the same individuals that were experiencing the acute phase of infection. 64 It seems that human‐inflated CD8+ T cells are more likely to perform cytolytic abilities, whereas murine CD8+ TE/M cells from memory inflation might generally mediate a widespread immune response via inflammatory cytokines releasing. 65 , 66 And according to the differences between human population and laboratory rodent in contacting various pathogens, environmental diversity might be another factor to prompted this controversial aspect of functional cytokines secreting from CD8+ TE/M cells. 67 , 68 It is also worth mention that modest amount of interleukin‐2 (IL‐2) is detected from CD8+ TE/M cells in patients at the acute phase, as well as virus‐specific CD8+ TE/M cells from infected mice in both acute and chronic phases. 11 , 69 But viral‐antigen nonspecific murine CD8+ TE/M cells with chronic infection could produce excessive IL‐2. 70 And recent studies have shown that autocrine IL‐2 programs the optimal secondary expansion of memory CD8+ T population in an acute infectious model due to the critical role of IL‐2 in deriving T cell priming. 28 Thus, we speculated that memory inflation derived CD8+ TE/M cells still exhibit self‐renewal ability via IL‐2 signalling pathway after viral clearance. Overall, other than surface markers, constitutively secreting of IFNγ, TNF and IL‐2 could be considered as the alternative characterization of memory inflated CD8+ T cells.

2.3. Inflation and exhaustion of CD8 + T cells after viral infection

Chronic viral infections involve a process of viral adaptation to the host, leading to various outcomes. 71 , 72 One example is CMV, which precisely adapts to the host by co‐evolving with the immune system and establishing a state of detente. 73 The latent virus sporadically reactivate when the host immune system is compromised, resulting in the generation of highly functional and resilient CD8+ T cells, as well as memory inflation. 65 , 74 On the other hand, partial adaptation to the host leads to persistent viral replication and antigen expression, causing cellular damage, immune dysfunction or exhaustion. 75 , 76 Consequently, severe chronic or progressive diseases could be ensued, such as comorbidity of human immunodeficiency virus and hepatitis B virus. 77 , 78 , 79 To gain deeper insights into the alternative immune responses triggered by latent and persistent viral infections, researchers have established a commonly utilized murine model with LCMV infection, which brings exhausted CD8+ T (TEX) cells. 24 , 80 It is well established that exhaustion occurs due to sustained stimulations by cognate antigens in driving CD8+ T cells to become reliant on antigenic signals for their survival. 81 Functionally, CD8+ TEX cells exhibit reduced proliferative capacity, cytotoxicity, and cytokine secretion. 82 In both murine models and human patients, CD8+ TEX cells are mainly characterized by elevated expression of the inhibitory receptors, include programmed death‐1 (PD‐1), CTLA‐4 and LAG3. 83 , 84 Besides, by lacking of KLRG1, CD127 and CD45RO (CD44 for murine model), the differentiation, secretion and proliferation abilities of CD8+ TEX cells are limited. 85 More specifically, a wide variety of other inhibitory markers were detected in CD8+ TEX cells, such as CD62L, TIGIT, TIM3 and CD160, thus prohibiting priming and activation. 86 Meanwhile, the effective function of CD8+ TEX cells gradually declines, accompanied by the losses of IL‐2, TNF, and IFNγ productions due to the irregular expressions of T‐bet and EOMES (Table 1). 87 , 88 Except the way of development of viral infection, exhaustion could be considered as the opposite status of memory inflation.

3. POTENTIAL MECHANISMS OF MEMORY INFLATION

In some infected individuals, the proportion of inflated CD8+ T cells can reach up to over 50% of total CD8+ T cells and last for years. 89 In murine models, the ratio of inflated CD8+ T cells attains over 70% at 1 month after CMV infection, while it comes to around 50% over 3 months post‐infection and stabilizes with this level for years. 40 However, on account of the dynamics of host immune landscape, inflated CD8+ T cells have been monitored to differentiate with numerous unforeseen consequences. 90 And up to date, the exactly mechanism that responsible for inflation of CD8+ T cells has not been clearly elucidated. 91 Here, we go through current knowledge for the potential aetiologies of memory inflation under viral infection.

3.1. Intrinsic and extrinsic roles of inflated CD8 + T cell formation

It is well‐recognized that the formation of inflationary CD8+ T cells has been ascribed to both intrinsic and extrinsic contexts, mainly depend on the expressions of proteasomes in immune cells and properties of viral epitopes, which affect the binding avidity and TCR affinity. 92 Current research studies identified that multi‐epitopes from viruses have the ability to provoke inflationary responses via inducing constitutively expression of proteasomes in non‐haematopoietic cells of host. 93 Studies on downstream proteins of proteasomes indicated that M27 favours peptide processing for MHC I presentation, which may enhance the activation of T cells to further form memory inflation via inhibiting the induction of immunoproteasomes. 94 On the other hand, M27 derived from CMV could also lead to ubiquitination of viral proteins and provide stress responses in attenuating viral activities and increasing cell viabilities in against infection. 95 In spite of CMV, this ubiquitin‐proteasome pathway was also observed to participate in the formation of memory T cells during the degradation of core proteins to eliminate replications of hepatitis B and influenza A virus. 96 , 97 , 98 Interestingly, the COVID‐19 virus were found to follow a similar manner to trigger memory inflation of T cells in certain conditions. 99 Actually, epidemiological reports from the past pandemic of COVID‐19 revealed that considerable numbers of individuals were observed to possess numerous virus‐specific CD8+ TE/M cells in circulating system for almost 1 year after infection, although most of them were evaluated to be asymptomatic patients. 100 Therefore, regardless of clinical symptoms, inflationary responses can be induced by viral peptides generated from the constitutive activation of proteasomes during the process of immune protection. 93 And memory inflation is believed to be a significant phenomenon that associated with the expression of proteasomes in non‐haematopoietic cells. 101 In addition, the CD8+ T cell subsets to recognize m139419–426 were monitored to have a phase of contraction with memory‐like phenotypes after rapid expansion, whereas no contraction phase is observed in the expansion of CD8+ T cells to recognize epitopes that located in M38316 and immediate early proteins (IE). 45 All of those epitopes were detected to be eliminated gradually due to the clearance of virus. 102 Therefore, we assumed that the changes of CD8+ T cell metabolism and function might perform as additional intrinsic manners to bias memory inflation.

In spite of the proteasome networks and metabolic changes in host's cells, viral epitopes have been identified to elicit persistent responses in priming T cells and then shape robust characteristics of memory inflationary phenotype. 103 , 104 For example, CMV lower matrix 65‐kDa phosphoprotein (pp65) (NLVPMVATV) epitope, which is usually considered as the marker for acute infection and presented by HLA‐A*0201 (A2/NLV), could initiate primed CD8+ T cells differentiated into effector and MP subsets, thus further give rise to the expansion of CD8+ TE/M cells. 105 Moreover, studies on human CMV (HCMV)‐encoded open reading frames‐mediated recall responses revealed that pp65 and UL123 (IE) could be recognized by more than half of the infected cohort and provoke greater responses in comparing to other antigens, such as pp150, gB, gH, pp50, and pp28. 104 Thus, pp65 and IE are not only responsible for clearance of virus‐infected cells at early stage, but also associated with the immune‐dominant antigens for memory CD8+ T cells generation. 104 Meanwhile, recent studies have demonstrated the decisive role of pp71 in enhancing the IE1‐derived peptides presenting by HLA class I molecules, thereby facilitate the formation of inflated CD8+ T cells. 106 By contrast, IE2‐pp86 was reported to downregulate chemokine expression during acute phase, and then impede the recruitment of CD8+ T cells, as well as the strength of anti‐viral immune response. 107 Similarly, gpUS18 and gpUS20 were also observed to facilitate the establishment of chronic infection, but not memory inflation by affecting NK cell function in acute phase (Table 2). 108 In chronic phase, gpUS2, gpUS3, and gpUS11 jointly blocked the HLA class I pathway to inhibit proliferation and activation of memory CD8+ T cells. 109 , 110 Although numerous viral antigens were confirmed to participate the differentiation of CD8+ T cells with memory inflated phenotype, distinguish features of those antigens in serving CD8+ T cells' trajectories remain unveiled. 111 One hypothesis of peptide selection for memory inflation is the discrepancies in epitope‐display between priming and further differentiations, as well as expansions. 112 , 113 In acute phase of MCMV‐infection, C57BL/6 murine CD8+ T cells' responses were elicited to against at least 24 epitopes derived from 18 proteins, like M45, m141, M86, M57, M78, and M86. 28 , 45 Nevertheless, except promotion of host defences against infection, which facilitates long‐term antigen exposure and T cell recognition, none of those epitopes is directly associated with memory inflation. 114 , 115 On the other side, according to TCR specificities of inflated CD8+ T cells after infection, five singular epitopes (m139 419–426, M38 316–323, IE3 416–423, IE3 461–475, and M102 486–500) were found to dominate clonal expansion and recall response (Table 2). 28 , 45 Notably, two epitopes also encoded by IE3 (IE3416–423 and IE3461–475) are readily detectable in acute infection but exhibit constitutively expression at chronic phase. 45 This sequential expression pattern mainly depends on the virus duplication and spreading, but whether they determine the strength and/or persistence of memory inflation is not fully known. 116

TABLE 2.

Antigen epitopes from CMV and their potential intrinsic roles.

Antigen epitopes Roles and mechanism
HCMV
IE1‐pp71 Enhancing the presentation and supporting CD8+ recognition
IE2‐pp86 Inhibits the expression of chemokine
pp65

Inflationary phenotype;

Inhibits antiviral gene expression and IFN signalling

gpUS3 Downregulation of HLA class I pathway
gpUS2 and gpUS11 Degrade HLA class I molecules
gpUS18 and gpUS20 NK cell function
MCMV
M45 Acute phase of CD8+ T cells responses
m139 and M38 Inflationary phenotype

Except of the antigen specificities, initial viral titrations were revealed to exert promising effects for inflationary CD8+ T cells generation. 46 Low‐dose (less than 1 × 101 PFU) inoculation with CMV could dampen the inflated CD8+ T cells accumulation and lead to expansion of TCM phenotype for secondary response, which is more likely to happen in latency‐dominant response during chronic infection or vaccination. 117 , 118 Meanwhile, at the period of post‐infection, few CMV latency is found to remain in non‐haematopoietic cells, including vascular endothelial, lymph node interstitial, lung, and bone marrow cells, which are confirmed to be essential for driving antigen‐specific TCM and resident memory CD8+ T (TRM) cells proliferation, thus reducing TE/M population in circulating system. 43 , 117 , 119 By contrast, results from murine models indicated that CMV infection with a high‐dosage (more than 1 × 104 PFU) not only provokes a rigorous anti‐viral response, but also sharply deflates circulating CD44lowCD62L+KLRG1CD8+ TN cells and increases accumulation of CD8+ TE/M cells with CD44highCD62LKLRG1+ phenotype. 89 , 117 Presumably, NK cell‐mediated cytokine storm is supposed to benefit the differentiation of CD8+ TE/M cells via antigen‐independent manner. 120 Moreover, in the absence of immune‐evasion protein polymers, enhanced cross‐presentation might play a crucial role in priming CD8+ TN cells to TE/M phenotype thus facilitate memory inflation under excessive virus‐induced inflammation. 121 This notion is supported by the evidences from BATF3‐deficient mice with viral infection, by lacking of dendritic cells (DCs), disabled cross‐presentation affects a wide range of epitopes‐dependent differentiation of CD8+ TE/M cells. 122 , 123 Simultaneously, studies by using bone marrow chimeric mice with MHC or TAP knock‐down in DCs revealed that memory inflation is severely blocked after the impairment of cross‐presentation, but priming remains intact. 124

Overall, many sophisticated triggers have been identified to contribute for the development of memory inflation after CMV infection. In spite of the importance of antigen persistence in the formation of memory inflation, studies also revealed that sporadically reactivated virus from latency could be processed by the constitutive proteasome and presented by MHC class I molecules. 74 In addition, both infected somatic cells and cross‐primed/cross‐dressed DCs are observed to present viral antigens via endogenous antigen presentation pathway. 110 , 124 Besides, TCR signalling and co‐stimulatory molecules are contributing to inflationary CD8+ T cell differentiation in concomitant with multiple inflammatory cytokines, including IFNγ, IL‐12, and IL‐7. 125 It is worth to mention that activation of CD4+ T cells are considered to be one of the decisive factors in the formation of inflationary CD8+ T cell population as well. 64 , 126 Collectively, in view of the multi‐dimensional intrinsic factors and external conditions to orchestrate memory inflation, further investigation should be conducted to emerge the under mechanism for this apparent increase in heterogeneity of CD8+ T cells.

3.2. Functional proteins to maintain the inflationary populations

As the transcription factor for controlling proliferative potential, self‐renewal capacity, as well as terminally differentiated T cells generation, Tcf1 is considered to be one of the most important proteins to maintain memory inflation. 127 For keeping pluripotency of CD8+ TN and primed T cells at the initiation of memory inflation after infection, Tcf1 constitutively expresses in T cells with high proliferative activities. 128 Along with T cell differentiation, Tcf1 is detected to eliminate in terminal differentiated cells, such as TE and TEMRA cells, which show a relatively short life‐span and last for a few days in both circulating system and tissues. 127 , 129 Therefore, Tcf1 is recognized as additional marker for characterizing inflated CD8+ T cell subsets in associated with CD127 expression and the absence of KLRG1. 130 Meanwhile, this less‐differentiated population is mostly composed by antigen‐specific CD8+ TE/M cells that possesses self‐renewal ability through an antigen‐independent manner, and plays vital roles in the maintenance of inflationary population. 41 , 131 Besides, recent studies demonstrated that Tcf1 could also trigger CD8+ TCM cells in differentiating to inflationary TE/M cells during sporadic reactivation after virus clearance. 11 , 132 Furthermore, inflationary Tcf1+CD8+ T cells from lymph nodes asymmetrically differentiate into Tcf1 effector‐like T cells, which is necessary to sustain memory inflationary population. 42 Actually, on basis of epigenetic inheritance, Tcf1 expression is varying depending on the dynamic changes of cell status, and there is still controversial that Tcf1 signalling might have alternative functions in contributing the progression of memory inflation. 133

CD127 is a well‐documented subunit of IL‐7 receptor that controls T cell differentiation in secondary lymphoid organs. 134 , 135 Accordingly, the expression of CD127 mainly determines the phenotypic differentiation of T cells after antigen stimulation. 42 By receiving IL‐7 from fibroblastic reticular cells, CD127+CD8+ T cells further differentiated into CD8+ TMP cells, which are responsible for the origin and expansion of inflationary T cells. 136 Moreover, during the acute phase of viral infection, IL7/CD127 signalling additionally enhanced the proliferative and differentiative abilities of CD8+ TMP cells, thus partially resembled CD62L+CD27+ TCM cells with functions that generate inflationary CD8+ T cells in triggering secondary response. 21 Consequently, apart from the surface marker for CD8+ TE/M cells, the expression of CD127 retains the homeostasis of inflationary CD8+ T cell expansion. 137

KLRG1 is originally identified as the inhibitor for Cadherin family. 138 And KLRG1 expression in antigen‐stimulated T cells implies the failure of priming. 139 On the contrary, the absence of KLRG1 could unchain the secreting of inflammatory cytokines in CD8+ T cells, such as IFNγ and TNF. 140 Studies on establishment of memory inflation with CMV infection confirmed that early‐primed KLRG1CD8+ T cells directly contribute to form the trajectory from high avidity TCM precursors to inflationary T cell pool at latency phase. 89 The above observations indicate that KLRG1 negatively regulates inflationary functionality, and acts as a checkpoint in preventing excessive secondary immune responses. 141

Despite of the pivotal functions to induce M2 macrophage polarization and mediating phagocytosis, high level of CX3CR1 also brings both cytotoxicity enhancement and pro‐inflammatory cytokine secreting in CD8+ TE/M cells. 142 Unlike CD44, which is mainly detected in murine effector‐like T cells, CX3CR1 is often combined with CD27 expression to determine memory T cells in both mice and human at the early memory stage after CMV infection. 143 Meanwhile, CX3CR1 signal is demonstrated to participate in CD8+ T cell differentiation during viral infection, including expansion of CD8+ TE/M cells from TE and TCM cells, as well as stimulation of T cells with naïve status towards a more differentiated state. 143 Sustained CX3CR1 expression in TCM and TE/M populations gives rise to enhanced virus clearance at secondary infection. 144 Besides, diminished CD27 expression on inflationary CX3CR1+CD8+ T cells occurs at the time of TEMRA population development. 145 Pathologically, CD8+ TE/M cells would quickly expand and differentiate into large numbers of CD8+ TEMRA cells in responding to secondary infection, and CD27 likely to play a role in tapping asymmetric differentiation of TE/M cells for memory inflationary maintenance and producing CD8+ TEMRA cells via CD70 stimulation. 146 And the conversion of CD27dim from CD27+ is considered as a sign of losing long‐term memory in inflated CD8+ T cells. 147

4. MEMORY INFLATION AND DISEASES

4.1. Autoimmune neuropathy

Guillain‐Barré syndrome (GBS) is a rare autoimmune polyneuropathy that is characterized by autoantigen specific immune responses and T cells accumulation in peripheral nervous system. 148 Clinically, ascending demyelination of peripheral nerve tissues would cause flaccid paralysis, neuropathic pain, as well as respiratory repression with an approximately 3–7% of the mortality rate. 149 In addition to genetic susceptibility, environmental factors have been recognized as significant contributors to the development of GBS, with over 65% of GBS cases were found to occur after infectious diseases or vaccination. 150 , 151 Upon repeated stimulation and/or infection, dynamic changes of host immune background were believed to exacerbate potential cross‐reactivity between pathogens and antigens of nervous system in eliciting autoimmunity. 152 , 153 This autoimmune responses usually target proteins that specifically expressed in myelin and/or axons of the peripheral nervous system, resulting in demyelinating or axonal damage. 154

Other than Campylobacter jejuni (24.6%), many viruses are well‐documented to associate with GBS onset, including CMV (12.4%), Epstein–Barr virus (1.3%) and Zika virus. 155 Theoretically, virus‐induced highly proliferative CD8+ T cells are recruited at the injury site from circulating system and facilitate the progression of autoimmune peripheral neuropathy (APN). 150 Latest observations have revealed that these antigen‐specific CD8+ T cells exhibit cytolytic phenotypes and directly participate both demyelination and axons damage. 156 By utilizing a transgenic mouse model, Yang et al. revealed that constitutively expression of b7.2 with cd4 knockout results a spontaneous APN, which mimics most clinical and pathological features of GBS, and CD8+ TE/M cells dominant the pathogenesis of disease at the lesion site. 157 In parallel, partial sciatic nerve ligation boosted M1 macrophage polarization could also accelerate the onset of APN via provoking CD8+ TE/M cells in cd4 knockout mice. 150 However, apart from the phenotypic identification of CD8+ TE/M cells in triggering GBS, further studies should be done on the similarities of TCR repertoires between CD8+ TE/M cells in recognizing virus and autoantigen. 158 , 159 In addition, due to the delayed memory inflation after infection, there is a difficulty on occasion to determine the association between viral infection and APN, but investigations have demonstrated the 8 years earlier on average onset of GBS in population with CMV infected history by comparing with uninfected patients. 160 Collectively, inflated CD8+ T cells with effector/memory phenotypes from viral infection be responsible for GBS onset and progression.

There is a long‐time debate that whether CD8+ T cells act as a prominent factor in inducing multiple sclerosis (MS), which is considered as an incurable autoimmune disease in the central nervous system (CNS). 161 , 162 In recent years, clonal expansions of CD8+ T cells have been found to dominate the infiltrated T cell population in active MS lesions of patients. 163 Meanwhile, the abundance of CD8+ T cells surpasses that of CD4+ T cells at all stages of disease. 164 And knockout of CD4+ T cells in murine models of MS not only fails to alleviate the disease progression, but also actually exacerbates the symptoms. 165 Moreover, in experimental autoimmune encephalomyelitis murine model, the most widely used murine model to mimic MS, restimulated CD8+ T cells from MCMV co‐infection group exhibit higher responsive rate in comparing with CD8+ T cells from the group that solely induced by MOG35‐55. 166 Additionally, upon restimulation, CD8+ T cells showed less specific to MCMV antigenic peptides, but exhibited characteristics that similar with TE/M and TEMRA populations in responding to autoantigens from CNS. 166 Evidence from MS patients also revealed that expanded CD8+ T cells with Granzyme B secreting could recognize epitopes from both CMV and autoantigens to promote disease relapse and treatment‐resistance. 167 Phenotypically, this clonal‐expanded CD8+ T cells from patients are terminally differentiated and resemble the features of TEMRA as well. 18

In summary, mounts of studies indicated that the development of autoimmunity in nerve system is not only influenced by genetic background, but could also be provoked by environmental factors, such as viral infection. 168 , 169 Although limitation on directly obtaining the evidence from lesion sites of nervous system, but the observations of peripheral CD8+ TE/M and TEMRA cells in mediating autoimmunity at both patients and murine models implied that memory inflation acts a key role of APN development. 150 , 158 Accordingly, the dynamic change of peripheral CD8+ T cell phenotypes after CMV infection are presumably responsible for the pathogenesis and progression of certain autoimmune neuropathies. 170 Up to date, cross‐reactivity from virus‐specific inflated CD8+ T cells via molecular mimicry is believed to be the leading hypothesis of sequestered antigen recognition and autoimmune derivation. 29 , 171 Due to the significant roles of inflated CD8+ T cells in GBS/AIDP and MS onsets, it would be necessary to further dissect the potential regulatory roles of TMP, TE/M, and TEMRA populations in disease prevention and treatment (Figure 2).

FIGURE 2.

FIGURE 2

Memory inflation and diseases. Increased CD8+ TE/M and TEMRA cells when memory inflation occurs are strongly associated with autoimmune neuropathy, cancer, and vascular diseases, also they can affect the effectiveness of immunotherapy. GBS, Guillain‐Barré syndrome; MS, multiple sclerosis; irAEs, immune‐related adverse events. TMP, Memory precursor T cells; TE/M, Effector/Memory T cells; TEMRA, terminally differentiated effector memory T cells.

4.2. Cancer and immunotherapy

Epidemiologically, over 13% of cancer cases were attributed to infection‐related factors, which are accounting for 64% of them with viral infections. 172 , 173 Despiting the gene integration‐caused mutation, a high prevalence of CMV post‐infection was found in patients with various types of cancer. 174 And numerous studies have provided evidence that CMV may facilitate tumour progression and contribute to poor prognosis by remodelling tumour microenvironment, impacting T cell phenotypes, and suppressing the effects of antitumor therapy. 175 , 176 , 177 In patients with multi‐forms of glioblastoma (GBM), CMV antigen expression and its role in tumorigenesis have emerged as promising targets for immunotherapy (Table 3). During the acute phase of CMV infection, fibroblasts exhibit increased secretion of pro‐inflammatory factors, including IL‐6, TNFα, CCL2, CCL5, and GM‐CSF. Conversely, the secretion of anti‐inflammatory cytokines such as IL‐4, IL‐28A, CCL24 and SCF is reduced. 178 Both IL‐28A and SCF were confirmed to possess anti‐tumour effects, while higher levels of CCL24 could facilitate the prognosis in breast cancer. 179 , 180 Meanwhile, prolonged and repeatedly infection by CMV leads to progressive depletion of CD8+ TN cells and increase of CD8+ TE/M and CD8+ TEMRA populations with viral antigen specific profiles, which might potentially devastate the anti‐tumour responses from T cells. 181 , 182 After virus clearance, long‐term memory inflation was also demonstrated to contribute the formation of chronic inflammation thus improve the susceptibility of cancer. 183 , 184 And in cancer patients, accumulation of non‐tumour antigen specific CD8+ T cells with inflated phenotypes in peritumoral lesions impairs anti‐tumour responses and induces the progression of cancer. 185 Evidences from clinic examinations revealed that excessive inflated CD8+ T cells in peripheral system suggest a prominent severe symptoms and poor prognosis of patients. 186 , 187 The presence of cloned proliferating immune cells in GBM patients compromises the effectiveness of the immune system in mounting an anti‐tumour response. 188 For refractory and recurrent cases, a promising approach is observed in combination of antiviral therapy with chemotherapy. 189 , 190 More importantly, as the sign of memory inflation, reduction of CD8+ TN cells could dampen the immune responses for tumour antigens and neoantigens, thus further give rise to poor prognosis of cancer patients. 191 Conversely, by recruiting 28 patients with primary GBM for adjuvant therapy using autologous CMV‐specific T cells expanded in vitro, CMV‐specific T cells regained immune function and had the potential to trigger a bystander effect in responding to tumour‐associated antigens. 192 This particular phenomenon maybe derived from the cross‐presentation that is due to the isolation of immune milieu in CNS. 193 Moreover, it appears that peripheral inflationary CD8+ T cells that specific for CMV are less exhaustion and functionally energetic in comparing with tumour‐antigen specific T cells from draining lymph nodes of patients with cancer. 194 Accordingly, high frequency of inflationary T cell population from CMV infection may not simply be a “destroyer” or “bystander” in patients with cancer, further investigations are needed to dissect the attribution of viral‐mediated inflated CD8+ T cells in cancer progression.

TABLE 3.

Current clinical trials using cytomegalovirus‐targeting immunotherapy for patients with glioblastoma (accessed on 23 May 2021, ClinicalTrials.gov).

Intervention Enrolment Phase Duration NCT number Status
Safety and tolerability of VBI‐1901 vaccine candidate in patients with recurrent GBM 38 I/II 2017–2021 NCT03382977 Active, not recruiting
Autologous cytomegalovirus‐specific cytotoxic T cells combined with temozolomide (TMZ) 65 I/II 2016–2021 NCT02661282 Active, not recruiting
TMZ+ cytomegalovirus peptide (PEP‐CMV) vaccine 70 I 2016–2021 NCT02864368 Active, not recruiting
Cytomegalovirus pp65‐LAMP mRNA‐loaded dendritic cells (DCs) with or without autologous lymphocyte transfer, tetanus toxoid 42 I 2006–2022 NCT00639639 Active, not recruiting
pp65‐shLAMP DC with GM‐CSF 120 II 2016–2024 NCT02465268 Recruiting
TMZ+ human CMV pp65‐LAMP mRNA‐pulsed autologous DCs 100 II 2015–2020 NCT02366728 Active, not recruiting
TMZ+ Human CMV pp65‐LAMP mRNA‐pulsed autologous DCs containing GM‐CSF+ Tetanus‐Diphtheria Toxoid (Td)+ GM‐CSF+ 111‐Indium‐labeling of Cells for in vivo Trafficking Studies 48 II 2019–2023 NCT03927222 Recruiting
Temozolomide+ Radiotherapy with or without Valganciclovir 220 II 2019–2024 NCT04116411 Recruiting

Abbreviations: GM‐CSF, granulocyte–macrophage colony‐stimulating factor; HER, human epidermal growth factor receptor; HER‐CAR, HER chimeric receptor; LAMP, lysosome‐associated membrane protein.

Cancer immunotherapy utilizes the inherent capabilities of the immune system to activate or enhance immune responses against cancer cells. 195 Common immunotherapy approaches include immune checkpoint inhibitors (ICIs), chimeric antigen receptor T‐cell therapy, and vaccine therapy. 196 , 197 , 198 , 199 And ICIs is the most widely adopted immunotherapeutic method that achieves remarkable success in certain types of cancer, including melanoma, 199 non‐small cell lung cancer, 200 and haematological malignancies. 201 Nevertheless, on basis of the new indications in continually expanding, the gross response rate of ICIs is below 30%, which represents over 70% of the patients have to experience therapeutic resistance, immune‐related adverse events (irAEs), as well as hyper progression. 202 , 203 Recent studies from clinics indicated that the same ICIs therapeutic strategies exhibit alternative effects in patients with similar tumour burden and immune checkpoint expression level. 204 As both cytolytic cells for tumour and target cells of ICIs, CD8+ T cell is believed to play decisive role in affecting the anti‐tumour effects of ICIs. 205

It is well‐documented that accumulation of tumour antigen non‐specific CD8+ TE/M and TEMRA cells and decreasing of CD8+ TN and tumour antigen specific TMP cell populations lead to diminish the tumour cytotoxicity. 206 , 207 , 208 As the function of ICIs is mainly unchaining the inhibitory effect of immune checkpoint from co‐stimulatory signalling pathway, high levels of non‐specific CD8+ TE/M and TEMRA population could bring excessive systemic IL‐2, TNF, and IFNγ secreting, thus promote cytokine storm. 209 Additionally, less CD8+ TN cells imply a relatively weaker clonal expansion of T cells for tumour specific immune responses. 182 As a result, this particular immune background might increase the risk of therapeutic resistance and irAEs of ICIs. 210 Other than epigenetic alternations, CMV‐mediated memory inflation is considered as the most likely trigger to reduce CD8+ TN and TMP cell populations, as well as generate large amounts of CD8+ TE/M and TEMRA cells with virus‐antigen specific TCR. 211 , 212 Hence, in considering the highly infectious rate of CMV worldwide, memory inflation of CD8+ T cells is supposed to be one of the primary cause in inducing therapeutic resistance of ICIs treatment. 213 Likewise, due to the increased numbers and enhanced activity of inflated CD8+ T cells, CMV infection has also been repeatedly reported to be responsible for recurrent and refractory irAEs in patients after receiving ICIs treatment. 214 , 215 , 216 Unfortunately, although it is clear that post‐CMV infection impairs the efficacy of ICIs, but the exactly CD8+ T cell phenotypes in association with their immune functions to be attributed in responsible for certain poor prognoses of patients after ICIs treatment are still enigma (Figure 2).

Meanwhile, data from both in vitro and in vivo studies showed a promising result that CMV‐specific CD8+ T cells could significantly eliminate cancer cells. 217 , 218 This finding might provide an alternative immunotherapy approach for cancers. On basis of the self‐renewal ability, CMV‐specific CD8+ T cells possess cytolytic activities without further stimulation or manipulation. 217 ex vivo investigation confirmed that memory inflated CMV‐specific CD8+ T cells from peripheral blood could directly secret pro‐inflammatory cytokines. 219 Although these subsets exhibit less specificity for anti‐tumour responses, but their secreting features might partially release tumours from immunosuppressive microenvironment in certain circumstances. 219 Furthermore, several tumour types are found to contain CMV peptide epitopes on account of the virus latency, which could engage peripheral CD8+ T cells to expand into memory inflated phenotypes, and further improve the efficacy of CD8+ T cell‐based anti‐tumour responses, as well as ICIs treatment. 220 Hence, we could not entirely exclude the possibility that CMV infection‐mediated memory inflation of CD8+ T cells also facilitate to tumour microenvironment with non‐specific manner.

4.3. Vascular diseases

Cardio/cerebrovascular diseases are among the leading causes of mortality in the modern era. 221 Despite extensive histopathological research studies, arterial atherosclerosis has emerged as well‐documented occasionally pathological changes in both heart and brain strokes. 222 , 223 , 224 Mechanistically, most arterial atherosclerosis is observed to display a chronic characteristic in affecting the bloodstream at large and medium‐sized arteries. 225 , 226 The formation of thromboses in severely stenosed arteries eventually results in blood flow restriction and tissue hypoxia. 227 Consequently, irreversible damage occurs in tissues and organs under insufficient blood supplies. 228 , 229 This process was also recognized as the cause of myocardial infarction, heart failure, cerebral infarction, and peripheral vascular diseases. 230 , 231 Numerous prospective and retrospective studies revealed a significantly higher risk of atherosclerosis associated with diabetes, hyperlipidaemia, hypertension, smoking, insulin resistance, and family history. 232 However, the initial aetiology of atherosclerosis, the underlying cellular and molecular driving factors, and the influence of the external environment on its progression remain unclear.

Other than unregulated retention of lipoproteins‐mediated cholesterol buildup, emerging evidences from both basic and clinical research studies suggest that atherosclerosis should be redefined as a chronic inflammatory disease. 233 A constitutive sub‐inflammation is considered as a certain congenital factor to recruit immune cells in infiltrating into the atherosclerotic plaque. 234 Interestingly, epitopes from antigens of atherosclerosis, such as apolipoprotein B (ApoB) and LDL have similar immunological features with viral antigens, including CMV, HCV, and HPV. 216 By recognizing the core proteins of ApoB and LDL, immune cells led to atherosclerosis that similar with an autoimmune manner. 235 Meanwhile, both repeated and post viral infection are supposed to have close relationship with atherosclerosis onset. 236 , 237 , 238 Consequently, recent studies have highlighted the crucial role of CD8+ T cell heterogeneity in the development of atherosclerosis. 226 , 230 , 233 , 239 Observations from patients with coronary heart disease revealed that both peripheral and atherosclerotic plaques had increased cytotoxic T cells, which possess similar features of inflated CD8+ T cells and further accelerated disease progression. 239 In advanced atherosclerosis, other than cells belong to innate immune system, excessive expansion of infiltrating CD8+ T cells was found to dominate the immune microenvironment in lesion areas. 240 Recent studies have drawn a possibility explanation of CD8+ T cells promote lesion progression and plaque instability. 241 By secreting cytokines, CD8+ T cells with effector memory and/or terminal differentiated effector memory phenotypes exacerbate the inflammation and cause cytotoxicity to endothelial and other somatic cells. 241 , 242 Thus, significant attention has been directed towards the involvement of inflated CD8+ T cell subsets in atherosclerosis. 243 Although activated CD8+ T cells are demonstrated to participate in atherosclerosis progression, but up to date, no evidence is obtained to show the direct effect of CD8+ T cells in facilitating dieses onset. 239

Other than inducing of viperin in interacting with platelets, CMV is the major factor to generate memory inflationary immune background. 244 , 245 , 246 , 247 And numerous clinical studies have demonstrated that dynamic change of CD8+ T cell phenotypes is one of the decisive factors for vascular diseases after CMV infection. 248 , 249 Due to the expansion of inflationary CD8+ T cells with IFNγ secreting, a non‐selective inflammation might promotes atherosclerotic plaque formation. 250 According to the antigen‐independent manner of self‐renewal feature and enhanced infiltrated ability, CD8+ TE/M cells from memory inflation would prompt sustained chronic inflammation in the lesion sites of atherosclerosis. 251 Moreover, eliminating of CD8+ TN cell populations in memory inflation could also be a risk factor for cardio/cerebrovascular diseases, as CD8+ TN cells contributing to alleviate disease progression. 81 By adoptive transferring ApoB‐related peptide (p210) immunized CD8+ TN cells into ApoE−/− mice, strengthening innate immune responses were monitored in sites of atherosclerotic plaques. 81 Similarly, primed CD8+ T cells possess higher lytic activity to inhibit macrophage and pathological CD4+ T cells in ApoE−/− mice when vaccinated with the p210 vaccine. 239 , 252 However, limited research studies have explored the specific immune responses caused by CMV infection and their impacts on atherosclerosis. Simultaneously, the understanding of alternative roles of CD8+ T cell subsets in atherosclerosis progression is also unrevealed (Figure 2).

5. CONCLUDING REMARKS

Current studies have shown that CMV‐induced memory inflation involves both innate and adaptive immune responses in leading an antigen‐independent differentiations and immune function changes of CD8+ T cells. 129 The expansion and stabilization of circulating CD8+ TE/M cell populations could be considered as the major sign of memory inflation. 123 Consequently, these antigen‐specific CD8+ T cells with memory inflation phenotype play a crucial role in both antigen‐specific and non‐selective immunity. 111 And the onset and progression of various diseases, including autoimmune disorders, cancer, and cardio/cerebrovascular disorders, as well as resistance of immunotherapy have been demonstrated to link with inflationary CD8+ T cells. 150 , 188 , 208 , 250 However, the underlying mechanisms for maintaining memory inflation, and the cellular characteristics and key molecules of memory inflation in resulting disease development, remain largely unexplored. 59 , 89 , 112 , 253 Further investigations are required to clarify these discrepancies in order to develop novel therapeutic strategies for correcting this harmful change in the host immune background. Meanwhile, due to the inconsistencies in the phenotypic and functional features of memory‐inflated cells between human patients and rodent models, the potential mechanisms that are responsible for memory inflation initiation, such as intrinsic and extrinsic properties of viral antigens, still need further exploration. 40 , 254 , 255 Immune‐modulating approaches and new animal models will be provided by further investigating to prevent the development of memory inflation.

Overall, this review highlights the definition and origination of memory inflation, the distinctive phenotypes and functions of memory‐inflated cells. Owing to the significance of CMV‐mediated host immune background heterogeneity, and its potential impacts on autoimmune disorders, cancer, cardio/cerebrovascular disorders, and resistance of immunotherapy, the better understanding of memory inflation provides us an opportunity to beyond the acute phase of viral infection, and sheds a light on the long‐term influences of post‐infection in host immune system.

AUTHOR CONTRIBUTIONS

Mu Yang conceived the review article. Yanfei Li and Jie Xiao contributed to the initial drafting of the manuscript, table preparation, visualization, and overall editing. Mu Yang and Chen Li helped to modify the manuscript. Mu Yang and Chen Li contributed to conceptualisation, funding, overall supervision, and supported review development, overall editing, and critical overall manuscript revision. All authors read and approved the final manuscript.

FUNDING INFORMATION

This study was supported by grant ZYGX2021YGCX005 (to M.Y.) from the Medicine and Engineering Cross‐Innovation on Oncology of University of Electronic Science and Technology of China, grant 82300276 (to C.L.) from the National Natural Science Foundation of China, grant TB2022085 (to C.L.) from the Sichuan Postdoctoral Foundation, grant 2023NSFSC1643 (to C.L.) and grant 2023ZYD0045 (to M.Y.) from the Sichuan Natural Science Foundation, and Sichuan Young Talents Foundation (to M.Y.).

CONFLICT OF INTEREST STATEMENT

The authors declare no potential conflict of interest.

ACKNOWLEDGEMENT

The authors thank Xijing Yang form the Animal Experimental Center of West China Hospital, Sichuan University.

Li Y, Xiao J, Li C, Yang M. Memory inflation: Beyond the acute phase of viral infection. Cell Prolif. 2024;57(12):e13705. doi: 10.1111/cpr.13705

Yanfei Li and Jie Xiao contributed equally to this study.

Contributor Information

Chen Li, Email: chenliscu@163.com.

Mu Yang, Email: mu.yang@uestc.edu.cn.

REFERENCES

  • 1. Fang E, Liu X, Li M, et al. Advances in COVID‐19 mRNA vaccine development. Signal Transduct Target Ther. 2022;7(1):94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Singhal T. A review of coronavirus disease‐2019 (COVID‐19). Indian J Pediatr. 2020;87(4):281‐286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Raoult D, Zumla A, Locatelli F, Ippolito G, Kroemer G. Coronavirus infections: epidemiological, clinical and immunological features and hypotheses. Cell Stress. 2020;4(4):66‐75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Sekine T, Perez‐Potti A, Rivera‐Ballesteros O, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID‐19. Cell. 2020;183(1):158‐168.e114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Kedzierska K, Venturi V, Field K, Davenport MP, Turner SJ, Doherty PC. Early establishment of diverse T cell receptor profiles for influenza‐specific CD8(+)CD62L(hi) memory T cells. Proc Natl Acad Sci U S A. 2006;103(24):9184‐9189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. Wieland D, Kemming J, Schuch A, et al. TCF1(+) hepatitis C virus‐specific CD8(+) T cells are maintained after cessation of chronic antigen stimulation. Nat Commun. 2017;8:15050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Hofmann M, Wieland D, Pircher H, Thimme R. Memory vs memory‐like: the different facets of CD8(+) T‐cell memory in HCV infection. Immunol Rev. 2018;283(1):232‐237. [DOI] [PubMed] [Google Scholar]
  • 8. Acosta‐Ampudia Y, Monsalve DM, Rojas M, et al. Persistent autoimmune activation and proinflammatory state in post‐coronavirus disease 2019 syndrome. J Infect Dis. 2022;225(12):2155‐2162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Taeschler P, Adamo S, Deng Y, et al. T‐cell recovery and evidence of persistent immune activation 12 months after severe COVID‐19. Allergy. 2022;77(8):2468‐2481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Du J, Wei L, Li G, et al. Persistent high percentage of HLA‐DR(+)CD38(high) CD8(+) T cells associated with immune disorder and disease severity of COVID‐19. Front Immunol. 2021;12:735125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Klenerman P, Oxenius A. T cell responses to cytomegalovirus. Nat Rev Immunol. 2016;16(6):367‐377. [DOI] [PubMed] [Google Scholar]
  • 12. Appay V, Dunbar PR, Callan M, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med. 2002;8(4):379‐385. [DOI] [PubMed] [Google Scholar]
  • 13. Snyder CM, Cho KS, Bonnett EL, van Dommelen S, Shellam GR, Hill AB. Memory inflation during chronic viral infection is maintained by continuous production of short‐lived, functional T cells. Immunity. 2008;29(4):650‐659. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Fornara C, Furione M, Zavaglio F, et al. Slow cytomegalovirus‐specific CD4(+) and CD8(+) T‐cell differentiation: 10‐year follow‐up of primary infection in a small number of immunocompetent hosts. Eur J Immunol. 2021;51(1):253‐256. [DOI] [PubMed] [Google Scholar]
  • 15. Holtappels R, Freitag K, Renzaho A, Becker S, Lemmermann NAW, Reddehase MJ. Revisiting CD8 T‐cell ‘memory inflation’: new insights with implications for cytomegaloviruses as vaccine vectors. Vaccines (Basel). 2020;8(3):402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Curtis HA, Singh T, Newkirk MM. Recombinant cytomegalovirus glycoprotein gB (UL55) induces an autoantibody response to the U1‐70 kDa small nuclear ribonucleoprotein. Eur J Immunol. 1999;29(11):3643‐3653. [DOI] [PubMed] [Google Scholar]
  • 17. Wu CS, Chyuan IT, Chiu YL, Chen WL, Shen CY, Hsu PN. Preserved specific anti‐viral T‐cell response but associated with decreased lupus activity in SLE patients with cytomegalovirus infection. Rheumatology (Oxford). 2020;59(11):3340‐3349. [DOI] [PubMed] [Google Scholar]
  • 18. Rothe K, Quandt D, Schubert K, et al. Latent cytomegalovirus infection in rheumatoid arthritis and increased frequencies of cytolytic LIR‐1+CD8+ T cells. Arthritis Rheumatol. 2016;68(2):337‐346. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Luo XH, Meng Q, Rao M, et al. The impact of inflationary cytomegalovirus‐specific memory T cells on anti‐tumour immune responses in patients with cancer. Immunology. 2018;155(3):294‐308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Griessl M, Renzaho A, Freitag K, Seckert CK, Reddehase MJ, Lemmermann NAW. Stochastic episodes of latent cytomegalovirus transcription drive CD8 T‐cell “memory inflation” and avoid immune evasion. Front Immunol. 2021;12:668885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Grassmann S, Mihatsch L, Mir J, et al. Early emergence of T central memory precursors programs clonal dominance during chronic viral infection. Nat Immunol. 2020;21(12):1563‐1573. [DOI] [PubMed] [Google Scholar]
  • 22. White TM, Bonavita CM, Stanfield BA, Farrell HE, Davis‐Poynter NJ, Cardin RD. The CMV‐encoded G protein‐coupled receptors M33 and US28 play pleiotropic roles in immune evasion and alter host T cell responses. Front Immunol. 2022;13:1047299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Attaf M, Roider J, Malik A, et al. Cytomegalovirus‐mediated T cell receptor repertoire perturbation is present in early life. Front Immunol. 2020;11:1587. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Karrer U, Sierro S, Wagner M, et al. Memory inflation: continuous accumulation of antiviral CD8+ T cells over time. J Immunol. 2003;170(4):2022‐2029. [DOI] [PubMed] [Google Scholar]
  • 25. Karrer U, Wagner M, Sierro S, et al. Expansion of protective CD8+ T‐cell responses driven by recombinant cytomegaloviruses. J Virol. 2004;78(5):2255‐2264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Sierro S, Rothkopf R, Klenerman P. Evolution of diverse antiviral CD8+ T cell populations after murine cytomegalovirus infection. Eur J Immunol. 2005;35(4):1113‐1123. [DOI] [PubMed] [Google Scholar]
  • 27. Takamura S. Impact of multiple hits with cognate antigen on memory CD8+ T‐cell fate. Int Immunol. 2020;32(9):571‐581. [DOI] [PubMed] [Google Scholar]
  • 28. O'Hara GA, Welten SP, Klenerman P, Arens R. Memory T cell inflation: understanding cause and effect. Trends Immunol. 2012;33(2):84‐90. [DOI] [PubMed] [Google Scholar]
  • 29. Halenius A, Hengel H. Human cytomegalovirus and autoimmune disease. Biomed Res Int. 2014;2014:472978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Rousselière A, Delbos L, Bressollette C, Berthaume M, Charreau B. Mapping and characterization of HCMV‐specific unconventional HLA‐E‐restricted CD8 T cell populations and associated NK and T cell responses using HLA/peptide tetramers and spectral flow cytometry. Int J Mol Sci. 2021;23(1):263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Schober K, Fuchs P, Mir J, et al. The CMV‐specific CD8(+) T cell response is dominated by supra‐public clonotypes with high generation probabilities. Pathogens. 2020;9(8):650. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Mueller S, Rouse B. Immune responses to viruses. Clin Immunol. 2008;27:421‐431. [Google Scholar]
  • 33. van der Gracht ET, Schoonderwoerd MJ, van Duikeren S, et al. Adenoviral vaccines promote protective tissue‐resident memory T cell populations against cancer. J Immunother Cancer. 2020;8(2):e001133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401(6754):708‐712. [DOI] [PubMed] [Google Scholar]
  • 35. Tomiyama H, Matsuda T, Takiguchi M. Differentiation of human CD8(+) T cells from a memory to memory/effector phenotype. J Immunol. 2002;168(11):5538‐5550. [DOI] [PubMed] [Google Scholar]
  • 36. Sauce D, Larsen M, Leese AM, et al. IL‐7R alpha versus CCR7 and CD45 as markers of virus‐specific CD8+ T cell differentiation: contrasting pictures in blood and tonsillar lymphoid tissue. J Infect Dis. 2007;195(2):268‐278. [DOI] [PubMed] [Google Scholar]
  • 37. Klenerman P, Dunbar PR. CMV and the art of memory maintenance. Immunity. 2008;29(4):520‐522. [DOI] [PubMed] [Google Scholar]
  • 38. Samson LD, van den Berg SP, Engelfriet P, et al. Limited effect of duration of CMV infection on adaptive immunity and frailty: insights from a 27‐year‐long longitudinal study. Clin Transl Immunol. 2020;9(10):e1193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Sims S, Bolinger B, Klenerman P. Increasing inflationary T‐cell responses following transient depletion of MCMV‐specific memory T cells. Eur J Immunol. 2015;45(1):113‐118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus‐specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202(5):673‐685. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Smith CJ, Venturi V, Quigley MF, et al. Stochastic expansions maintain the clonal stability of CD8(+) T cell populations undergoing memory inflation driven by murine cytomegalovirus. J Immunol. 2020;204(1):112‐121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Welten SPM, Yermanos A, Baumann NS, et al. Tcf1(+) cells are required to maintain the inflationary T cell pool upon MCMV infection. Nat Commun. 2020;11(1):2295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Torti N, Walton SM, Brocker T, Rülicke T, Oxenius A. Non‐hematopoietic cells in lymph nodes drive memory CD8 T cell inflation during murine cytomegalovirus infection. PLoS Pathog. 2011;7(10):e1002313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Derhovanessian E, Maier AB, Hähnel K, et al. Infection with cytomegalovirus but not herpes simplex virus induces the accumulation of late‐differentiated CD4+ and CD8+ T‐cells in humans. J Gen Virol. 2011;92(Pt 12):2746‐2756. [DOI] [PubMed] [Google Scholar]
  • 45. Munks MW, Cho KS, Pinto AK, Sierro S, Klenerman P, Hill AB. Four distinct patterns of memory CD8 T cell responses to chronic murine cytomegalovirus infection. J Immunol. 2006;177(1):450‐458. [DOI] [PubMed] [Google Scholar]
  • 46. Abassi L, Cicin‐Sain L. The avid competitors of memory inflation. Curr Opin Virol. 2020;44:162‐168. [DOI] [PubMed] [Google Scholar]
  • 47. Nolz JC, Richer MJ. Control of memory CD8(+) T cell longevity and effector functions by IL‐15. Mol Immunol. 2020;117:180‐188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Wirth TC, Xue HH, Rai D, et al. Repetitive antigen stimulation induces stepwise transcriptome diversification but preserves a core signature of memory CD8(+) T cell differentiation. Immunity. 2010;33(1):128‐140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Song Y, Wang B, Song R, et al. T‐cell immunoglobulin and ITIM domain contributes to CD8(+) T‐cell immunosenescence. Aging Cell. 2018;17(2):e12716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50. Wu H, Tang X, Kim HJ, et al. Expression of KLRG1 and CD127 defines distinct CD8(+) subsets that differentially impact patient outcome in follicular lymphoma. J Immunother Cancer. 2021;9(7):e002662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51. Kilinc MO, Aulakh KS, Nair RE, et al. Reversing tumor immune suppression with intratumoral IL‐12: activation of tumor‐associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors. J Immunol. 2006;177(10):6962‐6973. [DOI] [PubMed] [Google Scholar]
  • 52. Voehringer D, Koschella M, Pircher H. Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1). Blood. 2002;100(10):3698‐3702. [DOI] [PubMed] [Google Scholar]
  • 53. Baaten BJ, Tinoco R, Chen AT, Bradley LM. Regulation of antigen‐experienced T cells: lessons from the quintessential memory marker CD44. Front Immunol. 2012;3:23. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54. Komatsu H, Inui A, Sogo T, et al. Large scale analysis of pediatric antiviral CD8+ T cell populations reveals sustained, functional and mature responses. Immun Ageing. 2006;3:11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55. Arens R, Loewendorf A, Redeker A, et al. Differential B7‐CD28 costimulatory requirements for stable and inflationary mouse cytomegalovirus‐specific memory CD8 T cell populations. J Immunol. 2011;186(7):3874‐3881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56. Welten SP, Redeker A, Franken KL, et al. The viral context instructs the redundancy of costimulatory pathways in driving CD8(+) T cell expansion. Elife. 2015;4:e07486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Gustafson CE, Qi Q, Hutter‐Saunders J, et al. Immune checkpoint function of CD85j in CD8 T cell differentiation and aging. Front Immunol. 2017;8:692. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58. Jameson SC, Masopust D. Understanding subset diversity in T cell memory. Immunity. 2018;48(2):214‐226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59. Hertoghs KM, Moerland PD, van Stijn A, et al. Molecular profiling of cytomegalovirus‐induced human CD8+ T cell differentiation. J Clin Invest. 2010;120(11):4077‐4090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60. Riera L, Gariglio M, Valente G, et al. Murine cytomegalovirus replication in salivary glands is controlled by both perforin and granzymes during acute infection. Eur J Immunol. 2000;30(5):1350‐1355. [DOI] [PubMed] [Google Scholar]
  • 61. Khairallah C, Déchanet‐Merville J, Capone M. γδ T cell‐mediated immunity to cytomegalovirus infection. Front Immunol. 2017;8:105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62. Tomiyama H, Takata H, Matsuda T, Takiguchi M. Phenotypic classification of human CD8+ T cells reflecting their function: inverse correlation between quantitative expression of CD27 and cytotoxic effector function. Eur J Immunol. 2004;34(4):999‐1010. [DOI] [PubMed] [Google Scholar]
  • 63. Ferreira VH, Kumar D, Humar A. Deep profiling of the CD8+ T‐cell compartment identifies activated cell subsets and multifunctional responses associated with control of cytomegalovirus viremia. Transplantation. 2019;103(3):613‐621. [DOI] [PubMed] [Google Scholar]
  • 64. Walton SM, Torti N, Mandaric S, Oxenius A. T‐cell help permits memory CD8(+) T‐cell inflation during cytomegalovirus latency. Eur J Immunol. 2011;41(8):2248‐2259. [DOI] [PubMed] [Google Scholar]
  • 65. van de Berg PJ, van Stijn A, Ten Berge IJ, van Lier RA. A fingerprint left by cytomegalovirus infection in the human T cell compartment. J Clin Virol. 2008;41(3):213‐217. [DOI] [PubMed] [Google Scholar]
  • 66. Biron CA, Tarrio ML. Immunoregulatory cytokine networks: 60 years of learning from murine cytomegalovirus. Med Microbiol Immunol. 2015;204(3):345‐354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67. Picker LJ, Singh MK, Zdraveski Z, et al. Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood. 1995;86(4):1408‐1419. [PubMed] [Google Scholar]
  • 68. Deng W, Lira V, Hudson TE, et al. Recombinant listeria promotes tumor rejection by CD8(+) T cell‐dependent remodeling of the tumor microenvironment. Proc Natl Acad Sci U S A. 2018;115(32):8179‐8184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69. Kelly CD, Welte K, Murray HW. Antigen‐induced human interferon‐gamma production. Differential dependence on interleukin 2 and its receptor. J Immunol. 1987;139(7):2325‐2328. [PubMed] [Google Scholar]
  • 70. Hashimoto M, Im SJ, Araki K, Ahmed R. Cytokine‐mediated regulation of CD8 T‐cell responses during acute and chronic viral infection. Cold Spring Harb Perspect Biol. 2019;11(1):a028464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71. Sandu I, Oxenius A. T‐cell heterogeneity, progenitor‐progeny relationships, and function during latent and chronic viral infections. Immunol Rev. 2023;316(1):136‐159. [DOI] [PubMed] [Google Scholar]
  • 72. Vella LA, Herati RS, Wherry EJ. CD4(+) T cell differentiation in chronic viral infections: the Tfh perspective. Trends Mol Med. 2017;23(12):1072‐1087. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73. Dupont L, Reeves MB. Cytomegalovirus latency and reactivation: recent insights into an age old problem. Rev Med Virol. 2016;26(2):75‐89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74. Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021;19(12):759‐773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75. Jin HT, Anderson AC, Tan WG, et al. Cooperation of Tim‐3 and PD‐1 in CD8 T‐cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A. 2010;107(33):14733‐14738. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76. Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. Cell. 2009;138(1):30‐50. [DOI] [PubMed] [Google Scholar]
  • 77. Griffiths PD. CMV as a cofactor enhancing progression of AIDS. J Clin Virol. 2006;35(4):489‐492. [DOI] [PubMed] [Google Scholar]
  • 78. Webster A, Lee CA, Cook DG, et al. Cytomegalovirus infection and progression towards AIDS in haemophiliacs with human immunodeficiency virus infection. Lancet. 1989;2(8654):63‐66. [DOI] [PubMed] [Google Scholar]
  • 79. Lepiller Q, Tripathy MK, Di Martino V, Kantelip B, Herbein G. Increased HCMV seroprevalence in patients with hepatocellular carcinoma. Virol J. 2011;8:485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80. Dominguez CX, Amezquita RA, Guan T, et al. The transcription factors ZEB2 and T‐bet cooperate to program cytotoxic T cell terminal differentiation in response to LCMV viral infection. J Exp Med. 2015;212(12):2041‐2056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81. Mueller SN, Ahmed R. High antigen levels are the cause of T cell exhaustion during chronic viral infection. Proc Natl Acad Sci U S A. 2009;106(21):8623‐8628. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82. Cicin‐Sain L, Arens R. Exhaustion and inflation at antipodes of T cell responses to chronic virus infection. Trends Microbiol. 2018;26(6):498‐509. [DOI] [PubMed] [Google Scholar]
  • 83. Day CL, Kaufmann DE, Kiepiela P, et al. PD‐1 expression on HIV‐specific T cells is associated with T‐cell exhaustion and disease progression. Nature. 2006;443(7109):350‐354. [DOI] [PubMed] [Google Scholar]
  • 84. Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439(7077):682‐687. [DOI] [PubMed] [Google Scholar]
  • 85. Wherry EJ, Ha SJ, Kaech SM, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 2007;27(4):670‐684. [DOI] [PubMed] [Google Scholar]
  • 86. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486‐499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87. Angelosanto JM, Blackburn SD, Crawford A, Wherry EJ. Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection. J Virol. 2012;86(15):8161‐8170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88. Paley MA, Kroy DC, Odorizzi PM, et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science. 2012;338(6111):1220‐1225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89. Baumann NS, Welten SPM, Torti N, et al. Early primed KLRG1‐ CMV‐specific T cells determine the size of the inflationary T cell pool. PLoS Pathog. 2019;15(5):e1007785. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90. Gabel M, Baumann NS, Oxenius A, Graw F. Investigating the dynamics of MCMV‐specific CD8(+) T cell responses in individual hosts. Front Immunol. 2019;10:1358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91. Welten SPM, Baumann NS, Oxenius A. Fuel and brake of memory T cell inflation. Med Microbiol Immunol. 2019;208(3–4):329‐338. [DOI] [PubMed] [Google Scholar]
  • 92. Wynn KK, Fulton Z, Cooper L, et al. Impact of clonal competition for peptide‐MHC complexes on the CD8+ T‐cell repertoire selection in a persistent viral infection. Blood. 2008;111(8):4283‐4292. [DOI] [PubMed] [Google Scholar]
  • 93. Hutchinson S, Sims S, O'Hara G, et al. A dominant role for the immunoproteasome in CD8+ T cell responses to murine cytomegalovirus. PLoS One. 2011;6(2):e14646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94. Khan S, Zimmermann A, Basler M, Groettrup M, Hengel H. A cytomegalovirus inhibitor of gamma interferon signaling controls immunoproteasome induction. J Virol. 2004;78(4):1831‐1842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95. Ynga‐Durand MA, Dekhtiarenko I, Cicin‐Sain L. Vaccine vectors harnessing the power of cytomegaloviruses. Vaccines (Basel). 2019;7(4):152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96. Kong F, You H, Kong D, Zheng K, Tang R. The interaction of hepatitis B virus with the ubiquitin proteasome system in viral replication and associated pathogenesis. Virol J. 2019;16(1):73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97. Khor R, McElroy LJ, Whittaker GR. The ubiquitin‐vacuolar protein sorting system is selectively required during entry of influenza virus into host cells. Traffic. 2003;4(12):857‐868. [DOI] [PubMed] [Google Scholar]
  • 98. Widjaja CE, Olvera JG, Metz PJ, et al. Proteasome activity regulates CD8+ T lymphocyte metabolism and fate specification. J Clin Invest. 2017;127(10):3609‐3623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99. Lineburg KE, Srihari S, Altaf M, et al. Rapid detection of SARS‐CoV‐2‐specific memory T‐cell immunity in recovered COVID‐19 cases. Clin Transl Immunol. 2020;9(12):e1219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS‐CoV‐2 assessed for up to 8 months after infection. Science. 2021;371(6529):eabf4063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101. Desterke C, Turhan AG, Bennaceur‐Griscelli A, Griscelli F. HLA‐dependent heterogeneity and macrophage immunoproteasome activation during lung COVID‐19 disease. J Transl Med. 2021;19(1):290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 102. Torres L, Tang Q. Immediate‐early (IE) gene regulation of cytomegalovirus: IE1‐ and pp71‐mediated viral strategies against cellular defenses. Virol Sin. 2014;29(6):343‐352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103. Cicin‐Sain L, Brien JD, Uhrlaub JL, Drabig A, Marandu TF, Nikolich‐Zugich J. Cytomegalovirus infection impairs immune responses and accentuates T‐cell pool changes observed in mice with aging. PLoS Pathog. 2012;8(8):e1002849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104. Waller EC, Day E, Sissons JG, Wills MR. Dynamics of T cell memory in human cytomegalovirus infection. Med Microbiol Immunol. 2008;197(2):83‐96. [DOI] [PubMed] [Google Scholar]
  • 105. Hanley PJ, Melenhorst JJ, Nikiforow S, et al. CMV‐specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo. Sci Transl Med. 2015;7(285):285ra263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106. Hesse J, Reyda S, Tenzer S, et al. Human cytomegalovirus pp71 stimulates major histocompatibility complex class i presentation of IE1‐derived peptides at immediate early times of infection. J Virol. 2013;87(9):5229‐5238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107. Taylor RT, Bresnahan WA. Human cytomegalovirus immediate‐early 2 protein IE86 blocks virus‐induced chemokine expression. J Virol. 2006;80(2):920‐928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108. Fielding CA, Weekes MP, Nobre LV, et al. Control of immune ligands by members of a cytomegalovirus gene expansion suppresses natural killer cell activation. Elife. 2017;6:e22206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109. Hesse J, Ameres S, Besold K, Krauter S, Moosmann A, Plachter B. Suppression of CD8+ T‐cell recognition in the immediate‐early phase of human cytomegalovirus infection. J Gen Virol. 2013;94(Pt 2):376‐386. [DOI] [PubMed] [Google Scholar]
  • 110. Frascaroli G, Lecher C, Varani S, et al. Human macrophages escape inhibition of major histocompatibility complex‐dependent antigen presentation by cytomegalovirus and drive proliferation and activation of memory CD4(+) and CD8(+) T cells. Front Immunol. 2018;9:1129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111. Kuhn R, Sandu I, Agrafiotis A, et al. Clonally expanded virus‐specific CD8 T cells acquire diverse transcriptional phenotypes during acute, chronic, and latent infections. Front Immunol. 2022;13:782441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112. Renzaho A, Schmiedeke JK, Griessl M, Kühnapfel B, Seckert CK, Lemmermann NAW. Transcripts expressed in cytomegalovirus latency coding for an antigenic IE/E phase peptide that drives “memory inflation”. Med Microbiol Immunol. 2019;208(3–4):439‐446. [DOI] [PubMed] [Google Scholar]
  • 113. Dekhtiarenko I, Ratts RB, Blatnik R, et al. Peptide processing is critical for T‐cell memory inflation and may Be optimized to improve immune protection by CMV‐based vaccine vectors. PLoS Pathog. 2016;12(12):e1006072. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114. Simpson J, Starke CE, Ortiz AM, et al. Multiple modes of antigen exposure induce clonotypically diverse epitope‐specific CD8+ T cells across multiple tissues in nonhuman primates. PLoS Pathog. 2022;18(7):e1010611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115. Materne EC, Lilleri D, Garofoli F, et al. Cytomegalovirus‐specific T cell epitope recognition in congenital cytomegalovirus mother‐infant pairs. Front Immunol. 2020;11:568217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116. Angulo A, Ghazal P, Messerle M. The major immediate‐early gene ie3 of mouse cytomegalovirus is essential for viral growth. J Virol. 2000;74(23):11129‐11136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 117. Redeker A, Welten SP, Arens R. Viral inoculum dose impacts memory T‐cell inflation. Eur J Immunol. 2014;44(4):1046‐1057. [DOI] [PubMed] [Google Scholar]
  • 118. Snyder CM, Cho KS, Bonnett EL, Allan JE, Hill AB. Sustained CD8+ T cell memory inflation after infection with a single‐cycle cytomegalovirus. PLoS Pathog. 2011;7(10):e1002295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119. Abana CO, Pilkinton MA, Gaudieri S, et al. Cytomegalovirus (CMV) epitope‐specific CD4(+) T cells are inflated in HIV(+) CMV(+) subjects. J Immunol. 2017;199(9):3187‐3201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 120. Waggoner SN, Cornberg M, Selin LK, Welsh RM. Natural killer cells act as rheostats modulating antiviral T cells. Nature. 2011;481(7381):394‐398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121. Munks MW, Pinto AK, Doom CM, Hill AB. Viral interference with antigen presentation does not alter acute or chronic CD8 T cell immunodominance in murine cytomegalovirus infection. J Immunol. 2007;178(11):7235‐7241. [DOI] [PubMed] [Google Scholar]
  • 122. Torti N, Walton SM, Murphy KM, Oxenius A. Batf3 transcription factor‐dependent DC subsets in murine CMV infection: differential impact on T‐cell priming and memory inflation. Eur J Immunol. 2011;41(9):2612‐2618. [DOI] [PubMed] [Google Scholar]
  • 123. Klenerman P. The (gradual) rise of memory inflation. Immunol Rev. 2018;283(1):99‐112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 124. Seckert CK, Schader SI, Ebert S, et al. Antigen‐presenting cells of haematopoietic origin prime cytomegalovirus‐specific CD8 T‐cells but are not sufficient for driving memory inflation during viral latency. J Gen Virol. 2011;92(Pt 9):1994‐2005. [DOI] [PubMed] [Google Scholar]
  • 125. Arens R, Schoenberger SP. Plasticity in programming of effector and memory CD8 T‐cell formation. Immunol Rev. 2010;235(1):190‐205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126. Snyder CM, Loewendorf A, Bonnett EL, Croft M, Benedict CA, Hill AB. CD4+ T cell help has an epitope‐dependent impact on CD8+ T cell memory inflation during murine cytomegalovirus infection. J Immunol. 2009;183(6):3932‐3941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 127. Utzschneider DT, Charmoy M, Chennupati V, et al. T cell factor 1‐expressing memory‐like CD8(+) T cells sustain the immune response to chronic viral infections. Immunity. 2016;45(2):415‐427. [DOI] [PubMed] [Google Scholar]
  • 128. Escobar G, Mangani D, Anderson AC. T cell factor 1: a master regulator of the T cell response in disease. Sci Immunol. 2020;5(53):eabb9726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 129. Smith CJ, Quinn M, Snyder CM. CMV‐specific CD8 T cell differentiation and localization: implications for adoptive therapies. Front Immunol. 2016;7:352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 130. Kratchmarov R, Magun AM, Reiner SL. TCF1 expression marks self‐renewing human CD8(+) T cells. Blood Adv. 2018;2(14):1685‐1690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 131. Schmueck‐Henneresse M, Sharaf R, Vogt K, et al. Peripheral blood‐derived virus‐specific memory stem T cells mature to functional effector memory subsets with self‐renewal potency. J Immunol. 2015;194(11):5559‐5567. [DOI] [PubMed] [Google Scholar]
  • 132. Cicin‐Sain L. Cytomegalovirus memory inflation and immune protection. Med Microbiol Immunol. 2019;208(3–4):339‐347. [DOI] [PubMed] [Google Scholar]
  • 133. Zhou X, Yu S, Zhao DM, Harty JT, Badovinac VP, Xue HH. Differentiation and persistence of memory CD8(+) T cells depend on T cell factor 1. Immunity. 2010;33(2):229‐240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 134. Pandit H, Valentin A, Angel M, et al. Step‐dose IL‐7 treatment promotes systemic expansion of T cells and alters immune cell landscape in blood and lymph nodes. iScience. 2023;26(2):105929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 135. Fry TJ, Mackall CL. The many faces of IL‐7: from lymphopoiesis to peripheral T cell maintenance. J Immunol. 2005;174(11):6571‐6576. [DOI] [PubMed] [Google Scholar]
  • 136. Knop L, Deiser K, Bank U, et al. IL‐7 derived from lymph node fibroblastic reticular cells is dispensable for naive T cell homeostasis but crucial for central memory T cell survival. Eur J Immunol. 2020;50(6):846‐857. [DOI] [PubMed] [Google Scholar]
  • 137. van Leeuwen EM, de Bree GJ, Remmerswaal EB, et al. IL‐7 receptor alpha chain expression distinguishes functional subsets of virus‐specific human CD8+ T cells. Blood. 2005;106(6):2091‐2098. [DOI] [PubMed] [Google Scholar]
  • 138. Banh C, Fugère C, Brossay L. Immunoregulatory functions of KLRG1 cadherin interactions are dependent on forward and reverse signaling. Blood. 2009;114(26):5299‐5306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 139. Herndler‐Brandstetter D, Ishigame H, Shinnakasu R, et al. KLRG1(+) effector CD8(+) T cells lose KLRG1, differentiate into all memory T cell lineages, and convey enhanced protective immunity. Immunity. 2018;48(4):716‐729.e718. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 140. Blaum F, Lukas D, Reddehase MJ, Lemmermann NAW. Localization of viral epitope‐specific CD8 T cells during cytomegalovirus latency in the lungs and recruitment to lung parenchyma by airway challenge infection. Life (Basel). 2021;11(9):918. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 141. Tata A, Dodard G, Fugère C, et al. Combination blockade of KLRG1 and PD‐1 promotes immune control of local and disseminated cancers. Onco Targets Ther. 2021;10(1):1933808. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 142. Böttcher JP, Beyer M, Meissner F, et al. Functional classification of memory CD8(+) T cells by CX3CR1 expression. Nat Commun. 2015;6:8306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 143. Gordon CL, Lee LN, Swadling L, et al. Induction and maintenance of CX3CR1‐intermediate peripheral memory CD8(+) T cells by persistent viruses and vaccines. Cell Rep. 2018;23(3):768‐782. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 144. Gerlach C, Moseman EA, Loughhead SM, et al. The chemokine receptor CX3CR1 defines three antigen‐experienced CD8 T cell subsets with distinct roles in immune surveillance and homeostasis. Immunity. 2016;45(6):1270‐1284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 145. Salumets A, Tserel L, Rumm AP, et al. Epigenetic quantification of immunosenescent CD8(+) TEMRA cells in human blood. Aging Cell. 2022;21(5):e13607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 146. Welten SP, Redeker A, Franken KL, et al. CD27‐CD70 costimulation controls T cell immunity during acute and persistent cytomegalovirus infection. J Virol. 2013;87(12):6851‐6865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 147. Lu J, Chen G, Sorokina A, et al. Cytomegalovirus infection reduced CD70 expression, signaling and expansion of viral specific memory CD8(+) T cells in healthy human adults. Immun Ageing. 2022;19(1):54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 148. Querol L, Lleixà C. Novel immunological and therapeutic insights in Guillain‐Barré syndrome and CIDP. Neurotherapeutics. 2021;18(4):2222‐2235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 149. Al‐Hakem H, Doets AY, Stino AM, et al. CSF findings in relation to clinical characteristics, subtype, and disease course in patients with Guillain‐Barré syndrome. Neurology. 2023;100(23):e2386‐e2397. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 150. Yang M, Shi XQ, Peyret C, et al. Effector/memory CD8(+) T cells synergize with co‐stimulation competent macrophages to trigger autoimmune peripheral neuropathy. Brain Behav Immun. 2018;71:142‐157. [DOI] [PubMed] [Google Scholar]
  • 151. Orlikowski D, Porcher R, Sivadon‐Tardy V, et al. Guillain‐Barré syndrome following primary cytomegalovirus infection: a prospective cohort study. Clin Infect Dis. 2011;52(7):837‐844. [DOI] [PubMed] [Google Scholar]
  • 152. Oladiran O, Yang M, Rivera VAG, et al. Murine cytomegalovirus infection in mice results in an acute inflammatory reaction in peripheral nerves. J Neuroimmunol. 2019;335:577017. [DOI] [PubMed] [Google Scholar]
  • 153. Finsterer J. Neurological adverse reactions to SARS‐CoV‐2 vaccines. Clin Psychopharmacol Neurosci. 2023;21(2):222‐239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 154. Yuki N, Hartung HP. Guillain‐Barré syndrome. N Engl J Med. 2012;366(24):2294‐2304. [DOI] [PubMed] [Google Scholar]
  • 155. Langerak T, van Rooij I, Doornekamp L, et al. Guillain‐Barré syndrome in Suriname; clinical presentation and identification of preceding infections. Front Neurol. 2021;12:635753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 156. Meier UC, Cipian RC, Karimi A, Ramasamy R, Middeldorp JM. Cumulative roles for Epstein‐Barr virus, human endogenous retroviruses, and human herpes virus‐6 in driving an inflammatory cascade underlying MS pathogenesis. Front Immunol. 2021;12:757302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 157. Yang M, Rainone A, Shi XQ, Fournier S, Zhang J. A new animal model of spontaneous autoimmune peripheral polyneuropathy: implications for Guillain‐Barré syndrome. Acta Neuropathol Commun. 2014;2:5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 158. Yang M, Peyret C, Shi XQ, et al. Evidence from human and animal studies: pathological roles of CD8(+) T cells in autoimmune peripheral neuropathies. Front Immunol. 2015;6:532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 159. Súkeníková L, Mallone A, Schreiner B, et al. Autoreactive T cells target peripheral nerves in Guillain‐Barré syndrome. Nature. 2024;626(7997):160‐168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 160. Leung J, Sejvar JJ, Soares J, Lanzieri TM. Guillain‐Barré syndrome and antecedent cytomegalovirus infection, USA 2009‐2015. Neurol Sci. 2020;41(4):885‐891. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 161. Denic A, Wootla B, Rodriguez M. CD8(+) T cells in multiple sclerosis. Expert Opin Ther Targets. 2013;17(9):1053‐1066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 162. Sinha S, Itani FR, Karandikar NJ. Immune regulation of multiple sclerosis by CD8+ T cells. Immunol Res. 2014;59(1–3):254‐265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 163. Babbe H, Roers A, Waisman A, et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med. 2000;192(3):393‐404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 164. Legroux L, Arbour N. Multiple sclerosis and T lymphocytes: an entangled story. J Neuroimmune Pharmacol. 2015;10(4):528‐546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 165. van Oosten BW, Lai M, Hodgkinson S, et al. Treatment of multiple sclerosis with the monoclonal anti‐CD4 antibody cM‐T412: results of a randomized, double‐blind, placebo‐controlled, MR‐monitored phase II trial. Neurology. 1997;49(2):351‐357. [DOI] [PubMed] [Google Scholar]
  • 166. Milovanovic J, Popovic B, Milovanovic M, et al. Murine cytomegalovirus infection induces susceptibility to EAE in resistant BALB/c mice. Front Immunol. 2017;8:192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 167. Casiraghi C, Shanina I, Cho S, Freeman ML, Blackman MA, Horwitz MS. Gammaherpesvirus latency accentuates EAE pathogenesis: relevance to Epstein‐Barr virus and multiple sclerosis. PLoS Pathog. 2012;8(5):e1002715. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 168. Jörg S, Grohme DA, Erzler M, et al. Environmental factors in autoimmune diseases and their role in multiple sclerosis. Cell Mol Life Sci. 2016;73(24):4611‐4622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 169. Getts DR, Chastain EM, Terry RL, Miller SD. Virus infection, antiviral immunity, and autoimmunity. Immunol Rev. 2013;255(1):197‐209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 170. Janahi EMA, Das S, Bhattacharya SN, et al. Cytomegalovirus aggravates the autoimmune phenomenon in systemic autoimmune diseases. Microb Pathog. 2018;120:132‐139. [DOI] [PubMed] [Google Scholar]
  • 171. HoHsieh A, Wang CM, Wu YJ, Chen A, Chang MI, Chen JY. B cell epitope of human cytomegalovirus phosphoprotein 65 (HCMV pp65) induced anti‐dsDNA antibody in BALB/c mice. Arthritis Res Ther. 2017;19(1):65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 172. Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016;4(9):e609‐e616. [DOI] [PubMed] [Google Scholar]
  • 173. de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8(2):e180‐e190. [DOI] [PubMed] [Google Scholar]
  • 174. Söderberg‐Nauclér C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J Intern Med. 2006;259(3):219‐246. [DOI] [PubMed] [Google Scholar]
  • 175. Krenzlin H, Behera P, Lorenz V, et al. Cytomegalovirus promotes murine glioblastoma growth via pericyte recruitment and angiogenesis. J Clin Invest. 2019;129(4):1671‐1683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 176. Kim J, Lee WW, Hwang ES. Human cytomegalovirus (HCMV)‐infected astrocytoma cells impair the function of HCMV‐specific cytotoxic T cells. J Korean Med Sci. 2020;35(27):e218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 177. Sampson JH, Mitchell DA. Is cytomegalovirus a therapeutic target in glioblastoma? Clin Cancer Res. 2011;17(14):4619‐4621. [DOI] [PubMed] [Google Scholar]
  • 178. Yang Z, Tang X, McMullen TPW, Brindley DN, Hemmings DG. PDGFRα enhanced infection of breast cancer cells with human cytomegalovirus but infection of fibroblasts increased prometastatic inflammation involving lysophosphatidate signaling. Int J Mol Sci. 2021;22(18):9817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 179. Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559‐572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 180. Korbecki J, Kojder K, Simińska D, et al. CC chemokines in a tumor: a review of pro‐cancer and anti‐cancer properties of the ligands of receptors CCR1, CCR2, CCR3, and CCR4. Int J Mol Sci. 2020;21(21):8412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 181. Parry EM, Lemvigh CK, Deng S, et al. ZNF683 marks a CD8(+) T cell population associated with anti‐tumor immunity following anti‐PD‐1 therapy for Richter syndrome. Cancer Cell. 2023;41(10):1803‐1816.e1808. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 182. Lee SW, Choi HY, Lee GW, et al. CD8(+) TILs in NSCLC differentiate into TEMRA via a bifurcated trajectory: deciphering immunogenicity of tumor antigens. J Immunother Cancer. 2021;9(9):e002709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 183. Liao CP, Booker RC, Brosseau JP, et al. Contributions of inflammation and tumor microenvironment to neurofibroma tumorigenesis. J Clin Invest. 2018;128(7):2848‐2861. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 184. Sarantis P, Trifylli EM, Koustas E, Papavassiliou KA, Karamouzis MV, Papavassiliou AG. Immune microenvironment and immunotherapeutic management in virus‐associated digestive system tumors. Int J Mol Sci. 2022;23(21):13612. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 185. Beyer M, Karbach J, Mallmann MR, et al. Cancer vaccine enhanced, non‐tumor‐reactive CD8(+) T cells exhibit a distinct molecular program associated with “division arrest anergy”. Cancer Res. 2009;69(10):4346‐4354. [DOI] [PubMed] [Google Scholar]
  • 186. Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev. 2009;22(1):76‐98. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 187. Yang B, Li X, Zhang W, et al. Spatial heterogeneity of infiltrating T cells in high‐grade serous ovarian cancer revealed by multi‐omics analysis. Cell Rep Med. 2022;3(12):100856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 188. Marx S, Wilken F, Miebach L, et al. Immunophenotyping of circulating and intratumoral myeloid and T cells in glioblastoma patients. Cancers (Basel). 2022;14(23):5751. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 189. Stragliotto G, Pantalone MR, Rahbar A, Bartek J, Söderberg‐Naucler C. Valganciclovir as add‐on to standard therapy in glioblastoma patients. Clin Cancer Res. 2020;26(15):4031‐4039. [DOI] [PubMed] [Google Scholar]
  • 190. Stragliotto G, Rahbar A, Solberg NW, et al. Effects of valganciclovir as an add‐on therapy in patients with cytomegalovirus‐positive glioblastoma: a randomized, double‐blind, hypothesis‐generating study. Int J Cancer. 2013;133(5):1204‐1213. [DOI] [PubMed] [Google Scholar]
  • 191. Maimela NR, Liu S, Zhang Y. Fates of CD8+ T cells in tumor microenvironment. Comput Struct Biotechnol J. 2019;17:1‐13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 192. Smith C, Lineburg KE, Martins JP, et al. Autologous CMV‐specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme. J Clin Invest. 2020;130(11):6041‐6053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 193. Dziurzynski K, Chang SM, Heimberger AB, et al. Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol. 2012;14(3):246‐255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 194. Weathers SP, Penas‐Prado M, Pei BL, et al. Glioblastoma‐mediated immune dysfunction limits CMV‐specific T cells and therapeutic responses: results from a phase I/II trial. Clin Cancer Res. 2020;26(14):3565‐3577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 195. Baxevanis CN, Perez SA, Papamichail M. Cancer immunotherapy. Crit Rev Clin Lab Sci. 2009;46(4):167‐189. [DOI] [PubMed] [Google Scholar]
  • 196. Igarashi Y, Sasada T. Cancer vaccines: toward the next breakthrough in cancer immunotherapy. J Immunol Res. 2020;2020:5825401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 197. Märkl F, Huynh D, Endres S, Kobold S. Utilizing chemokines in cancer immunotherapy. Trends Cancer. 2022;8(8):670‐682. [DOI] [PubMed] [Google Scholar]
  • 198. Ma S, Li X, Wang X, et al. Current progress in CAR‐T cell therapy for solid tumors. Int J Biol Sci. 2019;15(12):2548‐2560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 199. Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet. 2021;398(10304):1002‐1014. [DOI] [PubMed] [Google Scholar]
  • 200. Reck M, Remon J, Hellmann MD. First‐line immunotherapy for non‐small‐cell lung cancer. J Clin Oncol. 2022;40(6):586‐597. [DOI] [PubMed] [Google Scholar]
  • 201. Haslauer T, Greil R, Zaborsky N, Geisberger R. CAR T‐cell therapy in hematological malignancies. Int J Mol Sci. 2021;22(16):8996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 202. Berner F, Bomze D, Diem S, et al. Association of checkpoint inhibitor‐induced toxic effects with shared cancer and tissue antigens in non‐small cell lung cancer. JAMA Oncol. 2019;5(7):1043‐1047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 203. Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223‐249. [DOI] [PubMed] [Google Scholar]
  • 204. Liu J, Liu D, Hu G, et al. Circulating memory PD‐1(+)CD8(+) T cells and PD‐1(+)CD8(+)T/PD‐1(+)CD4(+)T cell ratio predict response and outcome to immunotherapy in advanced gastric cancer patients. Cancer Cell Int. 2023;23(1):274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 205. Tang R, Xu J, Zhang B, et al. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J Hematol Oncol. 2020;13(1):110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 206. Zhang G, Liu A, Yang Y, et al. Clinical predictive value of naïve and memory T cells in advanced NSCLC. Front Immunol. 2022;13:996348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 207. Xie YQ, Arik H, Wei L, et al. Redox‐responsive interleukin‐2 nanogel specifically and safely promotes the proliferation and memory precursor differentiation of tumor‐reactive T‐cells. Biomater Sci. 2019;7(4):1345‐1357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 208. Gebhardt T, Park SL, Parish IA. Stem‐like exhausted and memory CD8(+) T cells in cancer. Nat Rev Cancer. 2023;23(11):780‐798. [DOI] [PubMed] [Google Scholar]
  • 209. Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85‐96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 210. Chuah S, Lee J, Song Y, et al. Uncoupling immune trajectories of response and adverse events from anti‐PD‐1 immunotherapy in hepatocellular carcinoma. J Hepatol. 2022;77(3):683‐694. [DOI] [PubMed] [Google Scholar]
  • 211. Zangger N, Oxenius A. T cell immunity to cytomegalovirus infection. Curr Opin Immunol. 2022;77:102185. [DOI] [PubMed] [Google Scholar]
  • 212. Yao C, Lou G, Sun HW, et al. BACH2 enforces the transcriptional and epigenetic programs of stem‐like CD8(+) T cells. Nat Immunol. 2021;22(3):370‐380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 213. Zuhair M, Smit GSA, Wallis G, et al. Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta‐analysis. Rev Med Virol. 2019;29(3):e2034. [DOI] [PubMed] [Google Scholar]
  • 214. Lankes K, Hundorfean G, Harrer T, et al. Anti‐TNF‐refractory colitis after checkpoint inhibitor therapy: possible role of CMV‐mediated immunopathogenesis. Onco Targets Ther. 2016;5(6):e1128611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 215. Anastasopoulou A, Samarkos M, Diamantopoulos P, et al. Cytomegalovirus infections in patients treated with immune checkpoint inhibitors for solid malignancies. Open Forum Infect Dis. 2023;10(4):ofad164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 216. van Turenhout ST, Berghuis M, Snaebjornsson P, et al. Cytomegalovirus in steroid‐refractory immune checkpoint inhibition‐related colitis. J Thorac Oncol. 2020;15(1):e15‐e20. [DOI] [PubMed] [Google Scholar]
  • 217. Çuburu N, Bialkowski L, Pontejo SM, et al. Harnessing anti‐cytomegalovirus immunity for local immunotherapy against solid tumors. Proc Natl Acad Sci U S A. 2022;119(26):e2116738119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 218. Schuessler A, Smith C, Beagley L, et al. Autologous T‐cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res. 2014;74(13):3466‐3476. [DOI] [PubMed] [Google Scholar]
  • 219. Li M, Garforth SJ, O'Connor KE, et al. T cell receptor‐targeted immunotherapeutics drive selective in vivo HIV‐ and CMV‐specific T cell expansion in humanized mice. J Clin Invest. 2021;131(23):e141051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 220. Rosato PC, Wijeyesinghe S, Stolley JM, et al. Virus‐specific memory T cells populate tumors and can be repurposed for tumor immunotherapy. Nat Commun. 2019;10(1):567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 221. Camici GG, Liberale L. Aging: the next cardiovascular disease? Eur Heart J. 2017;38(21):1621‐1623. [DOI] [PubMed] [Google Scholar]
  • 222. Tarp JB, Jensen AS, Engstrøm T, Holstein‐Rathlou NH, Søndergaard L. Cyanotic congenital heart disease and atherosclerosis. Heart. 2017;103(12):897‐900. [DOI] [PubMed] [Google Scholar]
  • 223. Shea S, Navas‐Acien A, Shimbo D, et al. Spatially weighted coronary artery calcium score and coronary heart disease events in the multi‐ethnic study of atherosclerosis. Circ Cardiovasc Imaging. 2021;14(1):e011981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 224. Kong Q, Ma X, Li L, Wang C, Du X, Wan Y. Atherosclerosis burden of brain‐ and heart‐supplying arteries and the relationship with vascular risk in patients with ischemic stroke. J Am Heart Assoc. 2023;12(16):e029505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 225. Fong IW. Emerging relations between infectious diseases and coronary artery disease and atherosclerosis. CMAJ. 2000;163(1):49‐56. [PMC free article] [PubMed] [Google Scholar]
  • 226. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12(3):204‐212. [DOI] [PubMed] [Google Scholar]
  • 227. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868‐874. [DOI] [PubMed] [Google Scholar]
  • 228. Cummins EP, Crean D. Hypoxia and inflammatory bowel disease. Microbes Infect. 2017;19(3):210‐221. [DOI] [PubMed] [Google Scholar]
  • 229. Peters MC, Maas RGC, van Adrichem I, et al. Metabolic maturation increases susceptibility to hypoxia‐induced damage in human iPSC‐derived cardiomyocytes. Stem Cells Transl Med. 2022;11(10):1040‐1051. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 230. Wolf D, Ley K. Immunity and inflammation in atherosclerosis. Circ Res. 2019;124(2):315‐327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 231. Frostegård J. Immunity, atherosclerosis and cardiovascular disease. BMC Med. 2013;11:117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 232. Herrington W, Lacey B, Sherliker P, Armitage J, Lewington S. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ Res. 2016;118(4):535‐546. [DOI] [PubMed] [Google Scholar]
  • 233. Schaftenaar F, Frodermann V, Kuiper J, Lutgens E. Atherosclerosis: the interplay between lipids and immune cells. Curr Opin Lipidol. 2016;27(3):209‐215. [DOI] [PubMed] [Google Scholar]
  • 234. Bäck M, Weber C, Lutgens E. Regulation of atherosclerotic plaque inflammation. J Intern Med. 2015;278(5):462‐482. [DOI] [PubMed] [Google Scholar]
  • 235. Kobiyama K, Ley K. Atherosclerosis. Circ Res. 2018;123(10):1118‐1120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 236. McLaughlin MM, Ma Y, Scherzer R, et al. Association of viral persistence and atherosclerosis in adults with treated HIV infection. JAMA Netw Open. 2020;3(10):e2018099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 237. Bason C, Corrocher R, Lunardi C, et al. Interaction of antibodies against cytomegalovirus with heat‐shock protein 60 in pathogenesis of atherosclerosis. Lancet. 2003;362(9400):1971‐1977. [DOI] [PubMed] [Google Scholar]
  • 238. Jung SH, Lee KT. Atherosclerosis by virus infection—a short review. Biomedicine. 2022;10(10):2634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 239. Saigusa R, Winkels H, Ley K. T cell subsets and functions in atherosclerosis. Nat Rev Cardiol. 2020;17(7):387‐401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 240. Cochain C, Zernecke A. Protective and pathogenic roles of CD8(+) T cells in atherosclerosis. Basic Res Cardiol. 2016;111(6):71. [DOI] [PubMed] [Google Scholar]
  • 241. Depuydt MAC, Prange KHM, Slenders L, et al. Microanatomy of the human atherosclerotic plaque by single‐cell transcriptomics. Circ Res. 2020;127(11):1437‐1455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 242. Fernandez DM, Rahman AH, Fernandez NF, et al. Single‐cell immune landscape of human atherosclerotic plaques. Nat Med. 2019;25(10):1576‐1588. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 243. Schäfer S, Zernecke A. CD8(+) T cells in atherosclerosis. Cells. 2020;10(1):37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 244. Crumpacker CS. Invited commentary: human cytomegalovirus, inflammation, cardiovascular disease, and mortality. Am J Epidemiol. 2010;172(4):372‐374. [DOI] [PubMed] [Google Scholar]
  • 245. Epstein SE, Speir E, Zhou YF, Guetta E, Leon M, Finkel T. The role of infection in restenosis and atherosclerosis: focus on cytomegalovirus. Lancet. 1996;348(Suppl 1):s13‐s17. [DOI] [PubMed] [Google Scholar]
  • 246. Olofsson PS, Jatta K, Wågsäter D, et al. The antiviral cytomegalovirus inducible gene 5/viperin is expressed in atherosclerosis and regulated by proinflammatory agents. Arterioscler Thromb Vasc Biol. 2005;25(7):e113‐e116. [DOI] [PubMed] [Google Scholar]
  • 247. Assinger A, Kral JB, Yaiw KC, et al. Human cytomegalovirus‐platelet interaction triggers toll‐like receptor 2‐dependent proinflammatory and proangiogenic responses. Arterioscler Thromb Vasc Biol. 2014;34(4):801‐809. [DOI] [PubMed] [Google Scholar]
  • 248. Lv YL, Han FF, Gong LL, et al. Human cytomegalovirus infection and vascular disease risk: a meta‐analysis. Virus Res. 2017;227:124‐134. [DOI] [PubMed] [Google Scholar]
  • 249. Jia YJ, Liu J, Han FF, et al. Cytomegalovirus infection and atherosclerosis risk: a meta‐analysis. J Med Virol. 2017;89(12):2196‐2206. [DOI] [PubMed] [Google Scholar]
  • 250. Krebs P, Scandella E, Bolinger B, Engeler D, Miller S, Ludewig B. Chronic immune reactivity against persisting microbial antigen in the vasculature exacerbates atherosclerotic lesion formation. Arterioscler Thromb Vasc Biol. 2007;27(10):2206‐2213. [DOI] [PubMed] [Google Scholar]
  • 251. Du Y, Zhang G, Liu Z. Human cytomegalovirus infection and coronary heart disease: a systematic review. Virol J. 2018;15(1):31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 252. van Duijn J, Kritikou E, Benne N, et al. CD8+ T‐cells contribute to lesion stabilization in advanced atherosclerosis by limiting macrophage content and CD4+ T‐cell responses. Cardiovasc Res. 2019;115(4):729‐738. [DOI] [PubMed] [Google Scholar]
  • 253. Gugliesi F, Pasquero S, Griffante G, et al. Human cytomegalovirus and autoimmune diseases: where are we? Viruses. 2021;13(2):260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 254. Reddehase MJ, Lemmermann NAW. Cellular reservoirs of latent cytomegaloviruses. Med Microbiol Immunol. 2019;208(3–4):391‐403. [DOI] [PubMed] [Google Scholar]
  • 255. Bolinger B, Sims S, O'Hara G, et al. A new model for CD8+ T cell memory inflation based upon a recombinant adenoviral vector. J Immunol. 2013;190(8):4162‐4174. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cell Proliferation are provided here courtesy of Wiley

RESOURCES